Page last updated: 2024-08-21

pyrazines and favipiravir

pyrazines has been researched along with favipiravir in 501 studies

Research

Studies (501)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (2.59)	29.6817
2010's	152 (30.34)	24.3611
2020's	336 (67.07)	2.80

Authors

Authors	Studies
Egawa, H; Fukuda, Y; Furuta, Y; Kamiyama, T; Kozaki, K; Kuno, M; Minami, S; Narita, H; Nomura, N; Shiraki, K; Takahashi, K; Watanabe, Y	1
Egawa, H; Fukuda, Y; Furuta, Y; Kamiyama, T; Kozaki, K; Kuno, M; Minami, S; Nomura, N; Shiraki, K; Takahashi, K	1
Egawa, H; Furuta, Y; Kozaki, K; Kuno-Maekawa, M; Nomura, N; Sangawa, H; Shiraki, K; Takahashi, K; Uehara, S	1
Bailey, KW; Barnard, DL; Day, CW; Furuta, Y; Morrey, JD; Sidwell, RW; Smee, DF; Wong, MH	1
Furuta, Y; Julander, JG; Shafer, K; Sidwell, RW	1
Bailey, KW; Furuta, Y; Gowen, BB; Jung, KH; Mendenhall, M; Sanders, AB; Sidwell, RW; Wong, MH	1
Christensen, AJ; Furuta, Y; Morrey, JD; Siddharthan, V; Smee, DF; Taro, BS; Wang, H	1
Furuta, Y; Julander, JG; Morrey, JD; Shafer, K; Smee, DF	1
Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH	1
Hayden, F	1
Barnard, DL; Furuta, Y; Gowen, BB; Julander, JG; Morrey, JD; Sakamoto, K; Shiraki, K; Smee, DF; Takahashi, K	1
Furuta, Y; Julander, JG; Morrey, JD; Smee, DF	1
Egawa, H; Furuta, Y; Hurst, BL; Kadota, T; Smee, DF; Takahashi, K	1
Furuta, Y; Gowen, BB; Jung, KH; Morrey, JD; Smee, DF; Wong, MH	1
Bailey, KW; Furuta, Y; Hurst, BL; Morrey, JD; Smee, DF; Tarbet, EB; Wong, MH	1
Furuta, Y; Kawaoka, Y; Kiso, M; Le, QM; Ozawa, M; Sakabe, S; Sakai-Tagawa, Y; Shinya, K; Takahashi, K	1
Deyde, VM; Furuta, Y; Gubareva, LV; Klimov, AI; Mishin, VP; Sleeman, K	1
de la Torre, JC; Freiberg, AN; Furuta, Y; Gowen, BB; Holbrook, MR; Juelich, T; Mendenhall, M; Messina, EL; Nunberg, JH; Russell, A; Smee, DF	1
Buys, KK; Furuta, Y; Gowen, BB; Jung, KH; Smee, DF	1
Furuta, Y; Gowen, BB; Hall, JO; Mendenhall, M; Russell, A; Skirpstunas, R; Smee, DF	1
Babu, YS; Furuta, Y; Maekawa, M; Morrey, JD; Smee, DF; Tarbet, EB	1
Dallmeier, K; Jochmans, D; Leyssen, P; Nascimento, MS; Neyts, J; Rocha-Pereira, J	1
Lee, SM; Yen, HL	1
Armstrong, J; Baranovich, T; Govorkova, EA; Marjuki, H; Webby, RJ; Webster, RG; Wong, SS	1
Falzarano, D; Feldmann, H; Furuta, Y; Gowen, BB; Safronetz, D; Scott, DP	1
Deval, J; Jin, Z; Kim, B; Rajwanshi, VK; Smith, LK	1
Balzarini, J; Guddat, LW; Keough, DT; Meijer, J; Naesens, L; van Kuilenburg, AB; Vande Voorde, J	1
Furuta, Y; Komeno, T; Nishikawa, H; Nomura, N; Sangawa, H; Takahashi, K; Yoshida, A	1
Cao, B; Cao, RY; Kumaki, Y; Li, S; Xiao, JH; Zhong, W	1
Barnard, DL; Furuta, Y; Gowen, BB; Shiraki, K; Smee, DF; Takahashi, K	1
Barnard, DL; Furuta, Y; Hurst, BL; Smee, DF; Tarbet, EB; Vollmer, AH	1
Brasel, T; Freiberg, AN; Furuta, Y; Gowen, BB; Hill, TE; Juelich, TL; Pietzsch, C; Sefing, EJ; Smith, JK; Tigabu, B; Yun, T; Zhang, L	1
Eastaugh, LS; Lenk, RP; Lever, MS; Nelson, M; Smither, SJ; Steward, JA	1
Bailey, KW; Furuta, Y; Gowen, BB; Kumaki, Y; Scharton, D; Van Wettere, A; Vest, Z; Westover, JB	1
Günther, S; Lüdtke, A; Muñoz-Fontela, C; Oestereich, L; Rieger, T; Wurr, S	1
Bethel, LM; Caroline, AL; Hartman, AL; Oury, TD; Powell, DS; Reed, DS	1
Bernreuther, C; de Lamballerie, X; Emmerich, P; Günther, S; Krasemann, S; Lehmann, M; Neumann, M; Oestereich, L; Ölschläger, S; Rieger, T; Wurr, S	1
Hilgenfeld, R; Jochmans, D; Ma, Q; Nascimento, MS; Neyts, J; Rocha-Pereira, J	1
Bello, F; Dallmeier, K; de Lamballerie, X; Delang, L; Froeyen, M; Herdewijn, P; Jochmans, D; Leyssen, P; Martina, B; Neyts, J; Pastorino, B; Quérat, G; Segura Guerrero, N; Snijder, EJ; Tas, A; van Hemert, MJ	1
Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ	1
Kong, L; Li, Z; Shi, F; Xie, Y; Xu, W; Zhang, T	1
Appolinario, CM; Jackson, AC	1
Daikoku, T; Okuda, T; Shiraki, K; Yoshida, Y	1
Arias, A; Goodfellow, I; Thorne, L	1
Gulland, A	1
Anglaret, X; de Lamballerie, X; Guedj, J; Keïta, S; Malvy, D; Mentré, F; Taburet, AM	1
Mohammadi, D	1
Becker, S; Brodt, HR; de Leuw, P; Grünewald, T; Kann, G; Kempf, VA; Keppler, OT; Stephan, C; Vogl, T; Wolf, T; Zacharowski, K	1
Hasegawa, M; Ishii, M; Lefor, AK; Nagata, T	1
Nau, JY	2
Cohen, J; Kupferschmidt, K	1
Anglaret, X; Bouazza, N; de Lamballerie, X; Foissac, F; Frange, P; Guedj, J; Keïta, S; Malvy, D; Mentré, F; Taburet, AM; Treluyer, JM	1
Bavari, S; Cardile, AP; Mayers, DL	1
Court, MH; Epstein, CR; Giesing, D; Greenblatt, DJ; Harmatz, JS; Kadota, T; Kurosaki, C; Nakagawa, Y; Nakamura, T; Zhao, Y	1
Arnalich, F; Arribas, JR; Arsuaga, M; Borobia, AM; Carcas, AJ; de la Calle, F; Fernández-Puntero, B; Figueira, JC; Flores, E; García-de-Lorenzo, A; Jiménez-Yuste, V; Lago, M; Lasala, F; Mora-Rillo, M; Negredo, A; Nuñez, C; Ramírez-Olivencia, G; Sánchez-Seco, P; Viejo, A	1
Declerck, H; Decroo, T; Van Herp, M	1
Furuta, Y; Gowen, BB; Hagloch, J; Hall, JO; Sefing, EJ; Smee, DF; Westover, JB	1
Chappuis, F; Cherpillod, P; Cordey, S; Dayer, JA; Docquier, M; Gasche, Y; Iten, A; Kaiser, L; Petty, TJ; Pittet, D; Pugin, J; Rees, PSC; Samii, K; Sarria, FB; Schibler, M; Siegrist, CA; Simpson, AJH; Vetter, P; Vieille, G; Yerly, S; Zdobnov, EM	1
Blondiaux, J; Haque, A; Hober, D	1
Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY	1
Aso, M; Hasunuma, T; Kaneko, A; Kumagai, Y; Murakawa, Y; Noto, M; Oe, T; Sakurai, T; Yuji, W	1
de Lamballerie, X; Graw, F; Guedj, J; Günther, S; Madelain, V; Mentré, F; Nguyen, TH; Oestereich, L	1
Behera, I; Beigelman, L; Deval, J; Dyatkina, N; Jin, Z; Kao, CC; Lin, X; Rajwanshi, VK; Shaw, K; Symons, J; Tan, H; Tucker, K; Wang, G	1
Feldmann, H; Furuta, Y; Geisbert, J; Geisbert, TW; Gowen, BB; Komeno, T; Martellaro, C; Okumura, A; Rosenke, K; Safronetz, D; Saturday, G; Westover, JB	1
Antonini, M; Capobianchi, MR; Di Caro, A; Ippolito, G; Kobinger, GP; Lanini, S; Lauria, FN; Magrini, N; Nicastri, E; Petrosillo, N; Puro, V; Shindo, N	1
Bockholt, S; Günther, S; Krasemann, S; Lüdtke, A; Muñoz-Fontela, C; Oestereich, L; Pallasch, E; Rieger, T; Ruibal, P; Wurr, S	1
Furuta, Y; Komeno, T; Nishizono, A; Noguchi, K; Yamada, K	1
Bailey, KW; Bray, M; Dagley, A; Downs, B; Furuta, Y; Gowen, BB; Jung, KH; Sefing, EJ; Smee, DF; Van Wettere, AJ; Wandersee, L; Westover, JB	1
Neyts, J; Rocha-Pereira, J; Van Dycke, J	1
de Lamballerie, X; Guedj, J; Madelain, V; Mentré, F; Nguyen, TH; Olivo, A; Taburet, AM	1
Allaford Duverger, T; Anglaret, X; Antierrens, A; Arnould, I; Augier, A; Badir, J; Baize, S; Bangoura, N; Barbe, S; Baret, G; Barry, TS; Barte de Sainte Fare, E; Beavogui, AH; Bentahir, M; Berbain, E; Berette, S; Berutto, C; Bocquin, A; Bongono, A; Bore, JA; Camara, AM; Camara, D; Camara, FS; Camara, MS; Carazo, S; Carbonnelle, C; Carmoi, T; Carroll, M; Chanfreau Munoz, V; Colin, G; Colpaert, J; Conde, MN; D'Ortenzio, E; Danel, C; de Lamballerie, X; Deccache, Y; Defourny, I; Delamou, L; Di Caro, A; Diederich, S; Dindart, JM; Dortenzio, E; Doumbouya, L; Draguez, B; Dumont, C; Duraffour, S; Durant, JF; Eholie, SP; El Bakkouri, K; Etienne, A; Ezzedine, K; Fizet, A; Folkesson, E; Frange, P; Gabriel, M; Gala, JL; Gasasira Uwamahoro, M; Gonzalez, MC; Guedj, J; Günther, S; Gustin, L; Hinzmann, J; Irenge, L; Jansson, L; Keïta, S; Kerber, R; Kighoma, PM; Kolie, J; Komano, MS; Koundouno, FR; Kourouma, E; Kraus, A; Kuisma, E; Lamah, MC; Laouenan, C; Le Marcis, F; Lefevre, A; Leno, T; Levy-Marchal, C; Liedigk, B; Loua, CM; Loua, M; M'Lebing, AB; Maes, P; Malme, K; Malvy, D; Manfrin, E; Maomou, A; Massala, V; Mely, S; Mentre, F; Milinouno, A; Moh, R; Moumouni, K; Murgue, B; Ngabo, D; Nguyen, VK; Ombelet, S; Palich, R; Pannetier, D; Petitjean, F; Peyrouset, O; Piguet, P; Pizarro, L; Poelart, G; Poncin, M; Provost, C; Raoul, H; Rapp, C; Rudolf, M; Samake, N; Savini, H; Sekou, C; Shepherd, S; Sidiboun, AY; Sissoko, D; Smits, B; Soumah, A; Taburet, AM; Thom, R; Toufik, N; Tounkara, A; Tran-Minh, T; Treluyer, JM; Van Cauwenberghe, S; Van Herp, M; Verreckt, I; Wölfel, R; Yazdanpanah, Y; Yombouno, P	1
Abdoul, BM; Anglaret, X; Augier, A; Blackwell, N; Danel, C; Gala, JL; Kinda, M; Malvy, D; Palich, R; Petitjean, F; Peyrouset, O; Shepherd, S	1
Fouchier, RA; Jochmans, D; Neyts, J; Smits, SL; van den Hoogen, BG; van Nieuwkoop, S	1
Garcia-Alcalde, F; Govorkova, EA; Marathe, BM; Najera, I; Vogel, P; Webby, RJ; Webster, RG; Wong, SS	1
Ejima, M; Fujisaki, S; Furuta, Y; Kawaoka, Y; Neumann, G; Odagiri, T; Ogawa, R; Takashita, E; Tashiro, M	1
Yen, HL	1
Altmeyer, R; Gao, Q; Lan, K; Li, G; Wang, Y; Yuan, S; Zou, G	1
Balestra, P; Capobianchi, MR; Di Caro, A; Giancola, ML; Ippolito, G; Nicastri, E; Petrosillo, N; Ricottini, M	1
Bai, CQ; Cao, YX; Chen, YS; Dafae, F; Deng, YQ; Gao, GF; Hu, Y; Jiang, JF; Kanu, A; Kargbo, B; Kargbo, D; Liu, L; Liu, WS; Liu, WW; Liu, ZY; Lu, HJ; Mu, JS; Nie, WM; Niu, WK; Qian, J; Song, YB; Su, HX; Sun, Y; Tong, YG; Wang, CY; Wang, H; Wang, HQ; Wang, YP; Yan, T; Yang, F; Zhang, XG	1
Kraft, CS	1
Bank, C; Bolon, DN; Finberg, RW; Foll, M; Jensen, JD; Kowalik, TF; Liu, P; Matuszewski, S; Renzette, N; Shim, H; Wang, JP; Zeldovich, KB	1
Andrei, G; Gillemot, S; Lemey, P; Naesens, L; Rajwanshi, VK; Van Houdt, J; Vanderlinden, E; Vrancken, B	1
Carlson, RD; Crozier, I; Debiec, MR; Hill, CE; Kraft, CS; Kumar, G; Lyon, GM; Martin, DF; Mehta, AK; Nussenblatt, RB; Olsen, TW; Patel, PS; Ribner, BS; Shantha, JG; Smith, JR; Ströher, U; Uyeki, TM; Varkey, JB; Yeh, S	1
Delaune, D; Dufour-Gaume, F; Martinaud, C; Sailliol, A	1
Beigel, J; Davey, RT; Dodd, L; Fauci, AS; Koopmeiners, JS; Lane, HC; Malvy, D; Massaquoi, MBF; Neaton, J; Neuhaus Nordwall, J; Proschan, MA; Sahr, F; Tierney, J	1
de Ávila, AI; Domingo, E; Esteban, JI; Gallego, I; Gregori, J; Perales, C; Quer, J; Rice, CM; Soria, ME	1
Conrad, BL; Furuta, Y; Gowen, BB; Hickerson, BT; Jung, KH; Li, R; Miao, J; Nielson, S; Rigas, JD; Van Wettere, AJ; Wang, Z; Westover, JB	1
Azuma, T; Hisamatsu, K; Hosomaru, K; Ishida, M; Kunitou, M; Mikata, S; Mino, Y; Otomo, K; Shimizu, M; Yunoki, A	1
Reina, J; Reina, N	1
Anglaret, X; Baize, S; Bore, JA; Carazo, S; Carbonnelle, C; Conde, MN; de Lamballerie, X; Gala, JL; Guedj, J; Jacquot, F; Laouénan, C; Madelain, V; Malvy, D; Mentré, F; Nguyen, TH; Pastorino, B; Piorkowski, G; Raoul, H; Rodallec, A; Sissoko, D; Taburet, AM	1
de Avila, AI; Domingo, E; Moreno, E; Perales, C	1
Abdelnabi, R; Beaucourt, S; Blanc, H; Canard, B; Delang, L; Froeyen, M; Imbert, I; Leyssen, P; Morais, ATS; Neyts, J; Vignuzzi, M	1
Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G	1
Ji, J; Liu, X; Tian, Y; Zhai, M; Zhang, J; Zhang, T	1
Honda, T; Sakai, M; Tokunaga, T; Tomonaga, K; Yamamoto, Y	1
Bei, Z; Cai, L; Dou, Y; Song, Y; Sun, Y; Wang, H; Xu, L; Zhang, D	1
Anglaret, X; Antierens, A; Beavogui, AH; Berbain, E; Camara, AM; Carazo Perez, S; Depoortere, E; Folkesson, E; Lefevre, A; Maes, P; Malme, KN; Malvy, JD; Ombelet, S; Piguet, P; Poelaert, G; Sissoko, D; Tounkara, A; Trbovic, P	1
Baz, M; Boivin, G; Goyette, N; Griffin, BD; Kobinger, GP	1
Daikoku, T; Mizuguchi, M; Obita, T; Shiraki, K; Takemoto, M; Yokoyama, T; Yoshida, Y	1
Furuta, Y; Komeno, T; Nakamura, T	1
Bailey, KW; Furuta, Y; Gowen, BB; Komeno, T; Sefing, EJ; Van Wettere, AJ; Wandersee, L; Westover, JB	1
Domingo, E; Escribano-Romero, E; Jiménez de Oya, N; Saiz, JC	1
Bank, C; Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Liu, P; Matuszewski, S; Ormond, L; Renzette, N; Wang, JP; Zeldovich, K	1
Biava, G; Brucato, A; Ippolito, G; Nicastri, E; Petrosillo, N; Uyeki, TM	1
Akondy, RS; Cannon, D; Ellebedy, AH; Harmon, JR; Klena, JD; Kraft, CS; Lyon, MG; McElroy, AK; Mehta, AK; Nichol, ST; Ribner, BS; Sette, A; Sidney, J; Spiropoulou, CF; Varkey, JB	1
Conrad, BL; Furuta, Y; Gowen, BB; Hickerson, BT; Jung, KH; Li, R; Miao, J; Nielson, S; Reynolds, ES; Rigas, JD; Thangamani, S; Van Wettere, AJ; Wang, Z; Westover, JB	1
Carrillo-Bustamante, P; Graw, F; Guedj, J; Günther, S; Nguyen, THT; Oestereich, L	1
Becker, S; Brown, S; De Leuw, P; Eickmann, M; Faber, K; Kann, G; Klena, JD; Kraft, CS; Lyon, GM; McElroy, A; Mehta, AK; Morales, A; Nichol, S; Patel, K; Raabe, VN; Rabenau, H; Ribner, BS; Rollin, PE; Schuettfort, G; Stephan, C; Strecker, T; Ströher, U; Vanairsdale, S; Varkey, JB; Wolf, T	1
Bergeron, É; Chatterjee, P; Flint, M; Nichol, ST; Scholte, FEM; Spiropoulou, CF; Welch, SR	1
Arima, N; Baba, M; Okamoto, M; Saijo, M; Sakakibara, N; Toyama, M	1
Brown, AN; Bulitta, JB; Kim, TH; Pires de Mello, CP; Pomeroy, JJ; Rodriquez, JL; Tao, X	1
Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM	1
Ippolito, G; Nicastri, E; Vairo, F	1
Drenzek, C; Kraft, CS; O'Neal, JP; Raabe, V	1
Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S	1
Jochmans, D; Neyts, J	1
Biava, G; Chinello, P; Ippolito, G; Nicastri, E; Petrosillo, N; Pittalis, S	1
Bavari, S; Bixler, SL; Bocan, TM; Cazares, LH; Donnelly, G; Epstein, C; Garza, NL; Giesing, D; Lenk, R; Liang, LF; Soloveva, V; Van Tongeren, SA; Warren, TK; Welch, L; Wells, J; Wetzel, KS	1
Bavari, S; Bixler, SL; Bocan, TM; Cazares, LH; Dong, L; Donnelly, G; Epstein, C; Garza, NL; Giesing, D; Koistinen, KA; Lenk, R; Liang, LF; Nuss, J; Soloveva, V; Van Tongeren, SA; Warren, TK; Welch, L; Wells, J; Wetzel, KS	1
Caluwaerts, S	1
Han, M; Huang, W; Li, X; Wu, X; Yu, F; Zhao, X	1
Banadyga, L; He, S; Qiu, X; Wong, G; Zhang, Z; Zhu, W	1
Kim, JA; Kumar, M; Seong, RK; Shin, OS	1
Bakonyi, T; Forgách, P; Gyuranecz, M; Marosi, A; Sulyok, KM	1
Emmott, E; Goodfellow, I; Jalal, H; Smielewska, A	1
Abdelnabi, R; Delang, L; Neyts, J	1
Carbonnelle, C; de Lamballerie, X; Guedj, J; Gunther, S; Jacquot, F; Madelain, V; Mentré, F; Nguyen, THT; Piorkowski, G; Raoul, H; Rodallec, A	1
Koraka, P; Kycko, A; Marzec, A; Orłowska, A; Osterhaus, ADME; Reichert, M; Smreczak, M; Trębas, P; Żmudziński, JF	1
Bonnac, LF; Geraghty, RJ; Patterson, SE; Qiu, L	1
Furuta, Y; Gowen, BB; Hickerson, BT; Jung, KH; Komeno, T; Westover, JB	1
de la Torre, JC	1
Dawes, BE; Freiberg, AN; Furuta, Y; Ikegami, T; Juelich, T; Kalveram, B; Komeno, T; Lee, B; Park, A; Smith, JK; Zhang, L	1
Check Hayden, E	1
Feldmann, F; Feldmann, H; Furuta, Y; Gowen, BB; Hanley, PW; Komeno, T; Lovaglio, J; Martellaro, C; Rosenke, K; Safronetz, D; Saturday, G; Scott, DP; Westover, JB	1
Huchting, J; Meier, C; Naesens, L; Nasser, H; Vanderlinden, E; Winkler, M	1
Arias, A; Bassi, MR; Meyn, P; Polacek, C; Sempere, RN	1
Feldmann, H; Furuta, Y; Gowen, BB; Haddock, E; Hanley, PW; Hawman, DW; Komeno, T; Meade-White, K; Rosenke, K; Williamson, B	1
Brown, AN; Bulitta, JB; Kaushik, A; Kim, TH; Pires de Mello, CP; Tao, X; Vicchiarelli, M	1
Banadyga, L; He, S; Qiu, X; Rahim, MN; Safronetz, D; Zhang, Z; Zhu, W	1
Saijo, M	1
Domingo, E; Esteban, JI; Gallego, I; García-Álvarez, M; García-Crespo, C; Gómez, J; Gómez-González, A; Gregori, J; Perales, C; Quer, J; Soria, ME; Valiergue, R	1
Baize, S; Barron, S; Carbonnelle, C; de Lamballerie, X; Fizet, A; Guedj, J; Jacquot, F; Lacarelle, B; Madelain, V; Mentré, F; Raoul, H; Reynard, S; Solas, C	1
Domingo, E; Esteban, JI; Gallego, I; Gregori, J; Guerrero-Murillo, M; Perales, C; Quer, J; Soria, ME	1
Barclay, WS; Fletcher, RA; Goldhill, DH; Lackenby, A; Langat, P; Te Velthuis, AJW; Zambon, M	1
Fukuma, A; Fukushi, S; Furuta, Y; Komeno, T; Morikawa, S; Nakajima, N; Saijo, M; Shimojima, M; Tani, H; Taniguchi, S; Uda, A	1
Barclay, WS; Galiano, M; Goldhill, DH; Kellam, P; Lackenby, A; Langat, P; Miah, S; Xie, H; Zambon, M	1
Kaptein, SJF; Neyts, J; Segura Guerrero, NA; Sharma, S	1
Baz, M; Boivin, G; Carbonneau, J; Cavanagh, MH; Rhéaume, C	1
Atkinson, C; Breuer, J; Brown, LK; Burns, SO; Goldstein, R; Jacobs, M; Lowe, DM; Roy, S; Ruis, C; Williams, R; Yara-Romero, E	1
Govorkova, EA; Marathe, BM; Pascua, PNQ; Vogel, P; Webby, RJ	1
Brasel, T; Comer, JE; Escaffre, O; Freiberg, AN; Juelich, TL; Kalveram, B; Massey, S; Neef, N; Perez, DD; Smith, J; Smith, JK; Zhang, L	1
Afrough, B; Akoi Bore, J; Anglaret, X; Arnold, U; Bah, A; Baum, JHJ; Beavogui, AH; Becker-Ziaja, B; Bockholt, S; Böttcher, JP; Cabeza-Cabrerizo, M; Camara, AM; Camino, A; Carroll, MW; Carter, L; Castro, CM; Cisse, SD; Colin, G; Cowley, LA; Di Caro, A; Diallo, B; Drury, P; Duraffour, S; Enkirch, T; Fleischmann, E; Formenty, P; Gabriel, M; Garcia-Dorival, I; Ghebreghiorghis, L; Günther, S; Gurry, C; Hetzelt, N; Hinzmann, J; Holm, T; Hugh Logue, C; Ippolito, G; Jaeger, A; Juchet, S; Kafetzopoulou, L; Keita, S; Kerber, R; Koivogui, L; Kolie, JS; Kosgei, A; Krumkamp, R; Kuisma, E; Lorenz, E; Magassouba, N; Malvy, D; Marchal, CL; May, J; Mazzarelli, A; Meisel, S; Mertens, M; Michel, J; Miranda, O; Nitzsche, K; Pallasch, E; Patrono, LV; Portmann, J; Raymond Koundouno, F; Repits, J; Rickett, NY; Rudolf, M; Sachse, A; Singethan, K; Sissoko, D; Stoecker, K; Vitoriano, I; Wölfel, R; Wurr, S; Yenamaberhan, RL; Zekeng, EG	1
Huchting, J; Meier, C; Naesens, L; Van Berwaer, R; Vanderlinden, E	1
Adhikari, NKJ; Bah, EI; Chan, A; Fowler, RA; Hajek, J; Kao, R; Kiiza, P; Kwon, HY; Lamah, MC; Lamontagne, F; Lee, JS; Mishra, S; Murthy, S; Siemieniuk, R; Teo, K	1
Borrego, B; Brun, A; de Ávila, AI; Domingo, E	1
Bailey, T; Boon, ACM; Bricker, TL; Diamond, MS; Gounder, AP; Jagger, BW; Janowski, AB; Kwon, JH; Shafiuddin, M; Wang, D; Williams, GD; Zhao, G	1
Bavari, S; Chitty, AJ; Espy, N; Garcia, K; Nagle, E; Palacios, G; Pfeffer, B; Sanchez-Lockhart, M; Warren, T; Wiley, M	1
Arias, A; Sempere, RN	1
Hayden, FG; Hurt, AC; Mifsud, EJ	1
Brocato, RL; Hooper, JW	1
De Clercq, E	1
Sun, P; Wong, G; Xia, X; Xue, X; Yan, L; Zheng, X; Zhu, Y	1
Daikoku, T; Fukuda, Y; Kawai, M; Morita, N; Nomura, N; Okuda, T; Shiraki, K; Takahashi, K; Takemoto, M; Tanaka, T	1
Furuta, Y; Kaimori, R; Kimitsuki, K; Komeno, T; Nakajima, N; Nishizono, A; Noguchi, K; Saito, N; Yamada, K	1
Chen, Z; Li, W; Song, R	1
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB	1
Cao, B; Chen, C; Fan, G; Guo, L; Hayden, FG; Horby, P; Lu, B; Pan, J; Salam, A; Wang, C; Wang, Y; Zheng, J	1
Dudley, H; Janowski, AB; Wang, D	1
Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A	1
Plemper, RK; Toots, M	1
Daikoku, T; Shiraki, K	1
Li, J; Qi, C; Shen, L; Wang, Y; Zhang, Q	1
Takashita, E	1
Best, T; Breuer, J; Illingworth, CJR; Lumby, CK; Oporto, M; Shah, D; Tutill, H; Veys, P; Williams, R; Worth, A; Zhao, L	1
Barron, S; Barrot, L; Carbonnelle, C; de Lamballerie, X; Duthey, A; Guedj, J; Jacquot, F; Lacarelle, B; Madelain, V; Mentré, F; Mundweiler, S; Raoul, H; Solas, C; Thomas, D; Vallvé, A	1
Dong, L; Gao, J; Hu, S	1
Cheng, YH; Fang, QQ; Huang, WJ; Li, XY; Liu, J; Meng, Y; Tan, MJ; Wang, DY; Wei, HJ	1
Duan, Y; Zhou, C; Zhu, HL	1
Anglaret, X; Baize, S; de Lamballerie, X; Graw, F; Guedj, J; Günther, S; Laouénan, C; Madelain, V; Malvy, D; Mentré, F; Nguyen, THT; Oestereich, L; Piorkowski, G; Raoul, H	1
Chen, XP; Du, YX	2
Jensen, JD; Lynch, M	1
Chan, MCW; Chen, D; Cheung, PP; Choy, KT; Chu, DKW; Huang, X; Hui, KPY; Kaewpreedee, P; Peiris, M; Sia, SF; Wong, AY; Yen, HL	1
Claus, M; Dauby, N; Dechamps, P; Gérard, M; Günther, S; Konopnicki, D; Mahieu, R; Malvy, D; Martin, C; Martiny, D; Morales, MA; Nasreddine, R; Perandones, C; Roman, A; Schuldt, G; Stevens, E; Swaan, C; Van den Wijngaert, S; Van Praet, S; Vandenberg, O; Veliziotis, I; Vlieghe, E	1
Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM	1
Şimşek Yavuz, S; Ünal, S	1
Costanzo, M; De Giglio, MAR; Roviello, GN	1
Hsueh, PR; Jean, SS; Lee, PI	1
Ge, J; Li, H; Liu, Z	1
Alkindi, N; Mazer-Amirshahi, M; Mehta, N; Pourmand, A	1
Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A	1
de Lamballerie, X; Eloy, P; Guedj, J; Malvy, D; Mentré, F; Solas, C; Touret, F	1
Delang, L; Neyts, J	1
Kawaoka, Y; Kiso, M; Yamayoshi, S	1
Lin, SX; Stephen, P; Thériault, JF; Wang, R; Zhang, WF	1
Baggett, MV; Rhee, EP; Shepard, JO; Sise, ME; Stevens, JS	1
Coomes, EA; Haghbayan, H	1
Alper, S; Altuğ, E; Çelebi, İ; Demirkesen, C; Ferhanoğlu, B; Kocatürk, E; Taşkın, B; Vural, S	1
Eto, M; Fujita, H; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K	1
Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P	1
Bailey-Elkin, BA; Götte, M; Mark, BL; Tchesnokov, EP	1
Campos, L; Gouveia, CC	1
Li, J; Wang, G; Wu, Z; Zhang, C; Zhao, H	1
Chen, D; Dong, L; Pan, X; Peng, C; Yang, L	1
Abe, T; Anzai, N; Mishima, E; Miyazaki, M	1
Hickman, CJ; Latner, DR; Lawson, B; Rota, PA; Suppiah, S	1
de Lamballerie, X; Extramiana, F; Malvy, D; Mentre, F; Taburet, AM	1
Avihingsanon, Y; Chumpangern, W; Jutivorakool, K; Paitoonpong, L; Putcharoen, O; Sriprasart, T; Srisawat, N; Thammathiwat, T; Tiankanon, K; Torvorapanit, P; Townamchai, N; Tungsanga, S; Udomkarnjananun, S	1
Li, C; Ren, L; Wang, L	1
Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M	1
Ikeda, T; Kondo, Y; Miyazaki, S; Yamashita, R	1
Doi, K; Hayase, N; Ikeda, M; Morimura, N; Moriya, K	1
Martinez, MA	1
Feldmann, F; Feldmann, H; Furuta, Y; Gowen, BB; Haddock, E; Hanley, PW; Hawman, DW; Komeno, T; Lovaglio, J; Meade-White, K; Nakajima, N; Nardone, G; Scott, D	1
Chujoh, S; Domi, H; Fukuoka, H; Matsuura, H; Nakagawa, J; Yamamura, H	1
Chen, CZ; Gorshkov, K; Lo, DC; Xu, M; Zheng, W; Zhu, W	1
Li, Z; Liu, Y; Wang, D	1
Ajaz, SJ; Banday, AH; Shameem, SA	1
Bellutti-Enders, F; Hartmann, K; Jamiolkowski, D; Leuppi-Taegtmeyer, A; Manjaly Thomas, ZR; Scherer Hofmeier, K; Steveling-Klein, E	1
Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD	1
Han, YJ; Ji, XY; Li, XX; Ma, CY; Ren, ZG; Wu, DD; Yan, JL	1
Akova, M; Alp, A; Alp, Ş; Çalık Başaran, N; İnkaya, AÇ; Karahan, S; Metan, G; Öz, ŞG; Özışık, L; Şahin, TK; Sain Güven, G; Taş, Z; Telli Dizman, G; Topeli, A; Ünal, S; Uyaroğlu, OA; Uzun, Ö; Zarakol, P	1
Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E	1
Arab-Zozani, M; Ghoddoosi-Nejad, D; Hassanipour, S	1
Tiwaskar, M; Vora, A	1
Deshpande, GA; Kaname, S; Kishimoto, M; Komagata, Y; Kurai, D; Ono, K; Shimasaki, T; Uchida, H	1
Li, Y; Miao, Z; Pan, Q; Peppelenbosch, MP; Wang, Y; Yu, P	1
Al-Yamani, MJ; Asdaq, SMB; Jomah, S	1
Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S	1
Aktaş, A; Aslan, R; Ataseven, H; Sayin, K; Tüzün, B	1
Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N	1
Dagley, A; Furuta, Y; Gebre, M; Julander, JG; Komeno, T; Nakajima, N; Smee, DF	1
Acar, T; Ari, A; Bozaci, I; Karatas, M; Simsek, C; Tatar, E; Uslu, A; Yildirim, AM; Yildirim, O	1
Inoue, KI; Sagawa, T; Takano, H	1
Ichinose, N; Iwasaki, Y; Kobayashi, T; Moriya, M; Oda, T; Oiwa, A; Okada, Y; Takahashi, H; Watanabe, T	1
Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T	1
Islam, MA; Nasir, M; Perveen, RA; Saha, SK; Selina, F; Talha, KA	1
Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P	1
Chishiki, M; Hashimoto, K; Hosoya, M; Kume, Y; Maeda, H; Maeda, R; Miyazaki, K; Norito, S; Ono, T; Sato, M; Suyama, K; Watanabe, M	1
Aykaç, K; Cengiz, AB; Ceyhan, M; Cura Yayla, BC; Derin Oygar, P; İlbay, S; Karahan, S; Kukul, MG; Laçinel Gürlevik, S; Özsürekçi, Y	1
Chae, H; Jeong, HJ; Jeong, K; Kim, S; Lee, G; Min, S; Namgoong, SK	1
Dauby, N; Konopnicki, D; Roman, A; Van Praet, S; Vanhomwegen, C; Veliziotis, I	1
Chachaima-Mar, J; Pérez-Castilla, J	1
Baba, T; Hagiwara, E; Higa, K; Ikeda, S; Iwasawa, T; Kaneko, T; Kitamura, H; Kitayama, T; Komatsu, S; Murohashi, K; Nakazawa, A; Niwa, T; Oda, T; Ogura, T; Okabayashi, H; Okuda, R; Otoshi, R; Sato, Y; Sekine, A; Shintani, R; Yamaya, T	1
Fukui, Y; Hatano, T; Kawagishi, T; Kawasuji, H; Kuwano, H; Miyajima, Y; Morinaga, Y; Okudera, H; Sakamaki, I; Shibuya, T; Takegoshi, Y; Tani, H; Ueno, A; Wakasugi, M; Yamamoto, Y	1
Goto, Y; Hiraiwa, H; Ishimoto, T; Jingushi, N; Kato, I; Koshi, E; Kosugi, T; Maruyama, S; Miyagawa, Y; Numaguchi, A; Okazaki, M; Ozaki, M; Saito, S; Tetsuka, N; Toyama, Y; Yagi, T; Yamamoto, T	1
Canard, B; Coutard, B; Decroly, E; Fattorini, V; Ferron, F; Huchting, J; Le, NT; Meier, C; Peersen, O; Piorkowski, G; Selisko, B; Shannon, A; Touret, F	1
Banno, S; Doi, Y; Hase, R; Hibino, M; Hirose, M; Homma, Y; Horiguchi, T; Ikeda, N; Imai, T; Iwata, M; Kabata, D; Kamio, T; Kasahara, H; Kasamatsu, Y; Kashizaki, F; Kato, H; Kato, Y; Kita, T; Koba, H; Kodama, N; Kondo, M; Koseki, T; Lim, CK; Maeki, T; Matsuyama, A; Miyata, M; Mutoh, Y; Nakagawa, A; Nakatsumi, H; Nakayama, E; Ogawa, T; Saijo, M; Shinoda, M; Shintani, A; Tajima, S; Taniguchi, S; Terada, M; Teramachi, M; Uchida, Y; Yamamoto, M; Yokota, K; Yokoyama, T; Yoshida, H; Yoshida, J; Yuzawa, Y	1
Aydın, A; Çekiç, D; Dheir, H; Genc, AB; Karabay, O; Kocayigit, H; Koroglu, M; Şenocak, D; Varım, C; Yaylaci, S	1
Altın, S; Barça, T; Bolat, E; Fikri, Bİ; Sokucu, SN; Toptaş, M; Tural Onur, S	1
McCullough, PA	1
Budhathoki, P; Khadka, S; Pokharel, N; Rashmi, P; Shah, PB; Shrestha, DB	1
Cao, R; Fu, D; Li, W; Wen, J; Zhao, L; Zhong, W	1
Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D	1
Abe, S; Fujimori, D; Kaizuka, H; Otsuki, S; Takeuchi, Y; Takoi, H; Togashi, Y; Wada, T	1
Guan, W; Lan, W; Ou, J; Wu, J; Wu, X; Yan, Y; Zhang, J; Zhang, Q; Zhao, S	1
Hirai, D; Seta, K; Yamashita, D	1
Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ	1
Lai, WF; Sreekanth Reddy, O	1
Aykac, K; Ceyhan, M; Ozsurekci, Y; Yayla, BCC	1
Abdelnabi, R; Annaert, P; Augustijns, P; Barthelemy, K; Bervoets, L; Boudewijns, R; Breuer, J; Cawthorne, C; Dallmeier, K; De Keyzer, C; Delang, L; Hens, B; Heylen, E; Jacobs, S; Kaptein, SJF; Langendries, L; Liesenborghs, L; Maas, E; Neyts, J; Pang, J; Rocha-Pereira, J; Rymenants, J; Seldeslachts, L; Solas, C; Spriet, I; Ter Horst, S; Thibaut, HJ; Van Buyten, T; Vande Velde, G; Vergote, V; Verougstraete, N; Weynand, B; Williams, R; Wouters, J; Zhang, X	1
Abed, Y; Baz, M; Boivin, G; Checkmahomed, L; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O	1
Anglaret, X; Binquet, C; Bouchet, S; Crémer, A; Darnaud, T; Dupouy, J; Duvignaud, A; Gimbert, A; Joseph, JP; Journot, V; Lebeaux, D; Lebel, J; Lefèvre, B; Lhomme, E; Malvy, D; Michel, JF; Nguyen, D; Onaisi, R; Orne-Gliemann, J; Peiffer-Smadja, N; Piroth, L; Pistone, T; Poitrenaud, D; Richert, L; Roussillon, C; Sitta, R; Thiébaut, R; Wittkop, L	1
Cheng, A; Gardiner, B; Hoy, JF; Lau, JSY; Lee, SJ; McMahon, JH; Molton, JS; Peleg, AY; Rogers, BA; Roney, J; Sasadeusz, J; Trubiano, J	1
Bologheanu, R; Faybik, P; Holzmann, H; Oesterreicher, Z; Santonja, I; Schiefer, J; Schubert, L; Steininger, C; Thalhammer, F; Thurnher, M; Tobudic, S; Winkler, S	1
Dauby, N	1
Ban, K; Choi, SW; Go, YY; Jung, E; Kim, SJ; Lee, J; Lee, JH; Moon, SH; Park, HJ; Park, SJ; Park, SM; Park, YG; Shin, JS	1
Boretti, A	1
Bazram, A; Fathalipour, M; Hassaniazad, M; Hassanipour, S	1
He, L; Hu, X; Liang, T; Liu, L; Lou, Y; Lu, X; Luo, R; Qiu, Y; Su, J; Xu, K; Yang, X; Yao, H; Zhao, Q	1
Ardjmand, M; Esfahani, MR; Khodashenas, B; Rad, AS	1
Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Korompoki, E; Migkou, M; Ntanasis-Stathopoulos, I; Psaltopoulou, T; Terpos, E; Tzanninis, IG	1
Demir, G; Dheir, H; Erdem, AF; Güçlü, E; Kocayiğit, H; Özmen Süner, K; Tomak, Y; Yaylacı, S	1
Alaskar, A; Aldibasi, O; Alharbi, A; Aljeraisy, M; AlJohani, S; Almaghaslah, M; Almutairi, B; Alothman, A; Alqahtani, H; Alsaedy, A; Arabi, Y; Bosaeed, M; Bouchama, A; Hussein, M; Mahmoud, E; Nashabat, M	1
Ansari, A; Barkate, H; Joshi, S; Parkar, J; Patil, S; Talwar, D; Tiwaskar, M; Vora, A	1
Banerjee, DI; Darji, SA; Lipsa Rath, S; Toor, HG	1
Vaidyanathan, G	1
Ghasemnejad-Berenji, M; Pashapour, S	1
Asaruddin, MR; Bhawani, SA; Law, WY; Mohamad, S	1
Al Bahrani, M; Al Balushi, Z; Al Barwani, U; Al Lawati, A; Al Naabi, H; Al Salmi, I; Al Sharji, M; Al-Zakwani, I; Ambusaidi, Z; Khamis, F; Pandak, N	1
Hase, R; Ishida, K; Kurita, T; Mito, H; Muranaka, E; Sasazawa, H; Yano, Y	1
Barkate, H; Caracta, CF; Kadam, J; Patil, S; Pendse, A; Rangwala, S; Singh, P; Tandon, M; Udwadia, ZF; Wu, W	1
Amel Jamehdar, S; Milani, N; Movaqar, A; Soleimanpour, S; Yaghoubi, A	1
Çağlayan, D; Erdem, HA; Gökengin, D; Işıkgöz Taşbakan, M; Korkma, PE; Sayıner, A; Taşbakan, MS; Yamazhan, T	1
Al-Khafaji, K; Alfasane, MA; Bhattacharje, G; Das, AK; Parvez, MAK; Rafi, MO; Rahman, MS; Taskin-Tok, T	1
Mishra, SK; Tripathi, T	1
Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Mashima, D; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y	1
Mori, M; Picarazzi, F; Saladini, F; Vicenti, I; Zazzi, M	1
Holland, TL	1
Korman, TM	1
Chao, CM; Chen, PJ; Lai, CC	1
Ambrosino, I; Barbagelata, E; Ciarambino, T; Corbi, G; Moretti, AM; Politi, C	1
Govil, A; Luckett, K; Miller-Handley, H	1
Durvasula, R; Durvasula, SR; Kunamneni, A; Maciorowski, D; Ogaugwu, C	1
Habib, AA; Hammad, SF; Kamal, AH; Megahed, SM	1
Kumar, D; Trivedi, N; Verma, A	1
Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A	1
Chakraborty, U; Chandra, A; Ghosh, S; Ray, AK	1
Farhadi, T; Hashemian, SM; Velayati, AA	1
Chen, G; Chen, X; Li, J; Qin, Y; Wang, G; Wang, K; Wei, M; Wu, Z; Yu, J; Zhang, C; Zhao, H; Zhu, Q	1
Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y; Yoshimatsu, L	1
Igari, H; Ishii, I; Nakada, TA; Sayama, M; Suzuki, T; Yamazaki, S	1
Akdeniz, N; Aksoy, H; Aslan Kayıran, M; Cebeci, F; Erdemir, VA; Gürel, MS	1
Guedj, J; Lingas, G; Rosenke, K; Safronetz, D	1
Ison, MG; Scheetz, MH	1
da Silva, S; Martinková, I; Petroušová, L; Rožnovský, L	1
Wen, S; Xu, X; Yadav, AK; Yu, L	1
Keestra, S; Pepperrell, T; Pilkington, V; Rodgers, F	1
Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M	1
Saladini, F; Vicenti, I; Zazzi, M	1
Abu-Zaied, MA; Elgemeie, GH; Mahmoud, NM	1
Kutlu, Ö; Yılmaz, Ş	1
Abd-Elsalam, S; Badawi, R; Dabbous, HM; Ebeid, FFS; El Ghafar, MSA; El-Sayed, MH; Elbahnasawy, M; Sherief, AF; Soliman, S; Tageldin, MA	1
Metin, N; Turan, Ç	1
Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M	1
Barford, D; Castro-Hartmann, P; Coscia, F; Dent, K; Kimanius, D; Löwe, J; Muir, KW; Naydenova, K; Peet, MJ; Qian, P; Russo, CJ; Sader, K; Sutherland, JD; Wu, LF; Zhang, Z	1
Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M	1
Bermejo, F; Bernal-Bello, D; Duarte-Millán, MÁ; Farfán-Sedano, AI; Frutos-Pérez, B; García-Gil, M; García-Parra, CJ; Gonzalo-Pascua, S; Hernández-Muniesa, B; Jaenes-Barrios, B; Madroñal-Cerezo, E; Morales-Ortega, A; Ontañón-Nasarre, A; Rivas-Prado, L; Ruiz-Giardín, JM; San Martín-López, JV	1
Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R	1
Igari, H; Ikusaka, M; Kasai, H; Sakao, S; Shimada, R; Takayanagi, S; Taniguchi, T; Tawara, J; Uehara, T; Yahaba, M	1
Uslu, S	1
Barkate, H; Caracta, CF; Patil, S; Rangwala, S; Tandon, M; Udwadia, ZF; Wu, W	1
Medisetty, MK; Patel, A; Pujari, S	1
Abdel-Naby, NS; Ayyad, MM; Badr, KA; Rezk, MR	1
Moriiwa, Y; Morikawa, G; Okazawa, K; Yanagida, A	1
Azuma, T; Furumoto, A; Haku, T; Hidaka, M; Himeji, D; Ikeda, K; Ishida, M; Ishimaru, T; Kadowaki, N; Kakihana, Y; Kamikokuryo, C; Kaneko, M; Kawamura, M; Kurosu, T; Ohge, H; Saijo, M; Sakabe, S; Shimojima, M; Suemori, K; Takahashi, T; Takenaka, K; Taniguchi, T; Yamanaka, A; Yasukawa, M; Yoshikawa, T	1
Aytaç, P; Demiray, G; Doğan-Kurtoğlu, E; Erenmemişoğlu, A; Güney, B; Nacak, M; Ozbek, M; Sağlam, O; Saraner, N; Sevici, G; Ulusoy, MG	1
Adcock, IM; Bassir, A; Dalil Roofchayee, N; Dezfuli, NK; Jamaati, H; Marjani, M; Mehrian, P; Moniri, A; Mortaz, E; Mumby, S; Rezaei, M; Tabarsi, P; Varahram, M	1
Akca, HN; Akinci, E; Asfuroglu, E; Ates, I; Aydogan, S; Aypak, A; Bastug, A; Bilgic, Z; Bodur, H; Buzgan, T; Cıvak, M; Erdem, D; Eser, F; Guner, R; Gursoy, FM; Hasanoglu, I; Hezer, H; Izdes, S; Kaya Kalem, A; Kayaaslan, B; Kilic, H; Kucuksahin, O; Tezer Tekce, Y	1
Breuer, J; Brown, LK; Checkley, AM; Chowdhury, K; Dehbi, HM; Freemantle, N; Ikeji, F; Jones, G; Longley, N; Lowe, DM; Ndoutoumou, A; Santhirakumar, K; Standing, JF	1
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S	1
Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M	1
Altın, S; Arslan, MA; Baydili, KN; Çetinkaya, E; Çınarka, H; Çörtük, M; Günlüoğlu, G; Kıyık, M; Koç, AS; Koşar, F; Tanrıverdi, E; Yurt, S	1
Barthélémy, K; Cochin, M; Coutard, B; de Lamballerie, X; Driouich, JS; Guedj, J; Laprie, C; Lingas, G; Moureau, G; Nougairède, A; Petit, PR; Piorkowski, G; Solas, C; Touret, F	1
Achanta, PS; Chen, SN; Pauli, GF	1
Oruç, MA; Öz, H; Öztürk, O	1
Fukui, Y; Kaneda, M; Kawago, K; Kawasuji, H; Kimoto, K; Miyajima, Y; Morinaga, Y; Murai, Y; Ogami, C; Sakamaki, I; Takegoshi, Y; Tsuji, Y; Ueno, A; Yamamoto, Y	1
Celik, I; Duzgun, Z; Erol, M	1
Baillet, N; Baize, S; de Lamballerie, X; Gloaguen, E; Guedj, J; Madelain, V; Mullaert, J; Raoul, H; Reynard, S	1
Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA	1
Borrego, B; Brun, A; de la Losa, N; Moreno, S; Weber, F	1
Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T	1
Fujita, N; Ito, T; Kasamatsu, Y; Kunimitsu, K; Matsubara, S; Munakata, N; Sasao, A; Tsuboi, H; Tsuchido, Y; Yamawaki, M	1
Abalkhail, M; Al-Jeraisy, M; Alaskar, A; Aldibasi, O; Alhagan, K; Alharbi, A; AlJohani, S; Alothman, A; Alqahtani, H; Alsaedy, A; Alshamrani, M; Asiri, AM; Bosaeed, M; Hussein, M; Mahmoud, E; Musattat, A; Sultana, K	1
Bai, JY; Cui, N; Dai, K; Du, J; Fan, H; Fan, XJ; Fang, LQ; Hao, ZN; Jiang, XM; Li, H; Li, JX; Liu, HZ; Liu, W; Lu, QB; Peng, K; Song, YB; Wang, HQ; Wang, J; Wang, Z; Wang, ZB; Xiao, G; Xin, QL; Yang, Y; Yang, ZD; Yuan, C; Yuan, L; Yuan, YM; Zhang, DN; Zhang, L; Zhang, LK; Zhang, SF; Zhang, XA	1
Allahverdiyeva, S; Şentürk, Z; Yardım, Y; Yunusoğlu, O	1
Kami, M; Murayama, A; Ozaki, A; Tanimoto, T; Ueda, M	1
Abraham, I; Al-Jedai, A; Alajami, HN; Alali, AH; Alamer, A; Alfaifi, M; AlHassar, F; Alkharji, F; Almulhim, AS; Almutairi, M; Almutairi, W; Alosaimi, B; Alrashed, AA; Alsaeed, A; Baredhwan, AA; Howaidi, J; Mohzari, Y; Sulaiman, T	1
Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W	1
Fujii, S; Fujiya, Y; Fukudo, M; Ibe, Y; Inamura, H; Ishigo, T; Kunimoto, Y; Kuronuma, K; Nakata, H; Takahashi, S	1
Caferoğlu Sakat, S; Metin, N; Turan, Ç; Utlu, Z; Yıldız, TT	1
Aliota, MT; Bonnac, LF; Geraghty, RJ	1
Chang, X; Chen, G; Chen, X; Du, W; Gong, B; Ji, Y; Jiang, X; Jiang, Y; Li, G; Li, J; Li, N; Li, W; Liu, Y; Peng, P; Sun, W; Wang, G; Wang, Y; Wu, Z; Xiao, Z; Yao, J; Zeng, Q; Zhang, C; Zhao, H; Zhu, F; Zhu, Q	1
Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G	1
Demir, G; Dheir, H; Erdem, AF; Kalpakci, Y; Karacan, A; Kocayiğit, H; Süner, KÖ; Tomak, Y; Yaylacı, S	1
Gülseren, D; Yalıcı-Armagan, B	1
Indira, P; Md Nayeem, S; Sohail, EM; Srihari, NV; Srinivasa Reddy, M	1
Fukuoka, S; Imai, T; Kishaba, T; Maeda, A; Nabeya, D; Nagano, H; Narita, M; Shiiki, S; Takakura, S; Yokoyama, S	1
Bayrakci, B; Cengiz, AB; Gülhan, B; Gürlevik, SL; Kesici, S; Kurt Sukur, ED; Oygar, PD; Ozen, S; Ozsurekci, Y; Topaloglu, R	1
Akgun, H; Avci, D; Bilgin, M; Cerci, P; Efe, S; Ozmen, A; Ucan, A; Yagmuroglu, A	1
Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R	1
Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D	1
Akatsu, H; Kambayashi, D; Kudo, K; Manabe, T	1
Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Unlu, A; Yerlikaya, FH	1
Alkan, G; Artac, H; Emiroglu, M; Oz, SKT	1
Akinbami, O; Barclay, WS; Frise, R; Galiano, M; Gallego Cortés, A; Goldhill, DH; Lackenby, A; Miah, S; Shelley, J; Yan, A; Zambon, M; Zhou, J	1
Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR	1
A AlShahrani, S; A Enani, M; A Malhani, A; Halwani, R; R Alghareeb, M; Saheb Sharif-Askari, F; T Bin-Brikan, R; Tleyjeh, IM	1
Akbayrak, A; Atak, MF; Farabi, B; Kalelioğlu, MB; Rao, BK	1
Aktaş, A; Albayrak, İD; Hayran, Y; Öcalan, DT	1
Altun, D; Ömeroğlu, ŞK; Öztop, B; Temel, F	1
Doi, Y; Ide, T; Imai, T; Komoto, S; Lim, CK; Murata, T; Sakurai, A; Shintani, A; Suzuki, M	1
Grishina, M; Palko, N; Potemkin, V	1
Fukushi, S; Furuta, Y; Kato, H; Kawahara, M; Kitaura, S; Komeno, T; Nakajima, N; Saijo, M; Satoh, M; Takayama-Ito, M; Yoshikawa, T	1
Hashemian, SM; Khoundabi, B; Velayati, AA	1
Kulkarni, A; Nasa, P; Shrivastava, P; Singh, A; Vijayan, L	1
Cheung, PP; Chong, TH; Huang, X; Wang, Y; Xu, X; Yuan, C; Zhang, L	1
Ami, Y; Doan, YH; Li, TC; Muramatsu, M; Suzaki, Y; Takeda, N; Zhang, W	1
Ali, MK; Goto, M; Moniruzzaman, M; Moshikur, RM; Wakabayashi, R	1
Chao, CM; Hsueh, PR; Lai, CC	1
Kundu, S; Sarkar, D	1
Demir, B; Demir, E; Sütcüoğlu, O; Ünsal, O; Yazıcı, O	1
Ayıntap, E; Aytogan, H; Doran, MA	1
Eto, M; Fujita, H; Fukushima, S; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K	1
Chiba, N; Hata, M; Hidaka, S; Imai, T; Kikuchi, N; Sakurai, A; Sekimoto, M	1
Akcan, RE; Ergönül, Ö; Gönen, M; Kalender, M; Keske, Ş; Kozan, Ş; Özlüşen, B; Peltek, İB; Yaprak, D	1
Ali, MA; Bekheit, MS; Girgis, AS; Kandeil, A; Moatasim, Y; Mostafa, A; Panda, SS; Seliem, IA	1
Bhatti, K; Chidurala, RM; Das, R; Mehta, DK; Rana, M; Saini, M	1
Brasel, T; Comer, JE; Escaffre, O; Freiberg, AN; Ikegami, T; Juelich, TL; Kalveram, B; Massey, S; Neef, N; Perez, D; Smith, J; Smith, JK; Zhang, L	1
Kočišek, J; Luxford, TFM; Sedmidubská, B	1
Khaheshi, I; Shahrbaf, MA; Tabary, M	1
Dandapat, J; Padhi, AK; Saudagar, P; Tripathi, T; Uversky, VN	1
Berk, H; Demir Önder, K; Öztoprak, N; Seremet Keskin, A; Seyman, D	1
Mungmunpuntipantip, R; Wiwanitkit, V	2
Abedini, A; Abtahian, Z; Ashrafzadeh, M; Barati, S; Dastan, A; Dastan, F; Haseli, S; MohammadReza Hashemian, S; Sobhanian, A; Tabarsi, P; Yousefian, S	1
Ahmed, G; Alhashem, J; Alkhalifah, S; ALKhawajah, S; ALmarzooq, M; Almoosa, Z; Alshab, D; ALzain, M; Anshasi, N; Mansour, A; Mustafa, M; Mutair, AA; Qara, S; Saad, M	1
Kulkarni, A; Nasa, P; Shrivastava, PK; Singh, A; Vijayan, L	1
Gaspar, Z; Kiss-Dala, N; Lakatos, B; Lenart, KS; Petrik, B; Szabo, BG; Szlavik, J; Valyi-Nagy, I	1
Alkan, M; Demirkol, MA; Dinc, V; Esatoglu, SN; Kamat, S; Kostek, ME; Sargin Altunok, E; Satici, C; Toprak, ID; Yazla, S	1
Abbasov, H; Abishov, E; Aksu, T; Akyay, A; Albayrak, C; Andıç, N; Ar, MC; Ataş, Ü; Aydın Kaynar, L; Balık Aydın, B; Baş, V; Baydar, M; Beköz, HS; Beksaç, M; Bolaman, AZ; Can, F; Çelik, S; Çeneli, Ö; Cengiz Seval, G; Çiftçiler, R; Civriz Bozdağ, S; Demir, AM; Demirci, U; Demircioğlu, S; Diz Küçükkaya, R; Doğan, A; Eroğlu Küçükdiler, H; Erol, V; Göksoy, HS; Güler, N; Gündüz, E; Gürman, G; Gürsoy, V; Güven, ZT; Hindilerden, F; İlhan, O; İnce, İ; Kaynar, L; Keklik, M; Kurt Yüksel, M; Maral, S; Mutlu, YG; Özcan, M; Özkalemkaş, F; Özkocaman, V; Özkurt, ZN; Özsan, GH; Sadri, S; Selim, C; Sevindik, ÖG; Terzi, H; Topçuoğlu, P; Toprak, SK; Ünal, Ş; Üsküdar Teke, H; Yağcı, M; Yavaşoğlu, İ; Yavuz, B; Yavuz, Y; Yegin, ZA; Yılmaz, U; Yönal Hindilerden, İ; Yücel, OK	1
Alver, Ö; Ouma, CNM; Parlak, C; Ramasami, P; Rhyman, L	1
Cui, N; Fang, LQ; Li, H; Li, JC; Liu, W; Lu, QB; Lv, SM; Peng, XF; Song, YB; Wang, HQ; Yang, T; Yao, WS; Yuan, C; Yuan, Y; Zhang, DN; Zhang, XA; Zhao, J	1
Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X	1
Punyaratabandhu, P; Vanitchpongphan, S	1
Assis, LC; da Cunha, EFF; de Almeida La Porta, F; de Castro Ramalho, T; de Castro, AA; de Jesus, JPA; Kuca, K; Nepovimova, E	1
Hirota, T; Itoh, K; Iwasaki, H; Sakamaki, I	1
Chalermphunchai, N; Lelamali, K; Noppakun, K; Sawangduan, V; Sinpanee, T; Vongchaiudomchoke, T	1
Kahraman, ME; Özbuğday, Y; Yüksel, F	1
Chiaki, T; Kinjo, T; Kondo, D; Kubota, K; Minami, S; Moriiwa, Y; Morikawa, G; Okazawa, K; Takanashi, Y; Yanagida, A	1
Tsanni, A	1
Eloy, P; Guedj, J; Le Grand, R; Malvy, D	1
Al-Ardhi, FM; Al-Tannak, NF; Alhunayan, A; Novotny, L	1
Atli, Z; Aydin, T; Balkan, II; Fresko, I; Hamuryudan, V; Hatemi, G; Melikoglu, M; Ozcifci, G; Ozguler, Y; Oztas, M; Seyahi, E; Tabak, F; Ugurlu, S	1
Daye, M; Oltulu, P	1
Nayak, CA; Raiturcar, TP	1
Bengue, M; Choumet, V; de Lamballerie, X; Hamel, R; Liegeois, F; Missé, D; Nougairède, A; Pintong, AR; Pompon, J; Roques, P	1
Erk, N; Khoshnavaz, Y; Mehmandoust, M; Tuzen, M	1
Chen, H; Chen, J; Deng, W; Qiu, Z; Yang, C; Yang, S	1
Abdul Wahab, S; Adnan, NA; Cheng, JT; Chidambaram, SK; Chow, TS; Chuah, CH; Hor, CP; Ker, HB; Lee, HG; Lee, KS; Mustafa, M; Ng, TK; Nordin, N; Ong, SM; Tee, TY; Zaid, M; Zaidan, NZ	1
Abolnezhadian, F; Alavi, SM; Ghafourian, M; Khodadadi, A; Mahmoudian-Sani, MR; Nashibi, R; Sharhani, A; Shohan, M	1
Baig, MS; Li, P; Li, Y; Ma, Z; Pan, Q; Rajpoot, S; Saqib, U; Wang, Y; Yu, P	1
Tırmıkçıoğlu, Z	1
Doi, Y; Iwasaki, H; Koseki, T; Mizuno, T; Nakajima, K; Takahashi, K; Yamada, S	1
Chinnairusan, M; Dhanasekaran, S; Kagithakara Vajravelu, L	1
Hasan, SS; Kow, CS; Ramachandram, DS	1
Bonnac, LF; Cheeran, MC; Dreis, CD; Edwards, TC; Geraghty, RJ; Krishna, VD; Qiu, L; Soto-Acosta, R; Xie, J	1
Abdallah, IA; Bedair, A; Hammad, SF; Mansour, FR	1
Ikejima, K; Imai, R; Kurihara, Y; Matsusako, M; Ohde, S; Yamada, D	1
Arikan, H; Asicioglu, E; Barutcu Atas, D; Kaya, B; Tuglular, S; Tukenmez Tigen, E; Velioglu, A	1
Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F	1
Abalkhail, M; Ahmad, A; Al Aamer, K; Al Jeraisy, M; Alabdulkareem, K; Alanazi, M; Alaskar, A; Albaalharith, N; Aldibasi, O; Alhagan, K; Alharbi, A; Alharbi, NK; AlJohani, S; Almaziad, S; Alqahtani, H; Alrabiah, F; Alrehily, S; Alsaedy, A; Alshahrani, S; Alshamrani, M; Alshowair, A; Alturkistani, H; Bahlaq, M; Bosaeed, M; Gaifer, Z; Jaha, R; Jaser, S; Mahmoud, E; Musattat, A; Sultana, K; Tolbah, A	1
Ansari, A; Barkate, H; Bhagat, S; Dhar, R; Lakhe, M; Panchal, S; Patil, S; Talwar, D; Tiwaskar, M	1
Borku Uysal, B; Dokur, M; Islamoglu, MS; Onal, B	1
Kaszynski, RH; Matsumoto, S; Sakai, K; Sato, N; Shiraki, K; Takemoto, M	1
Abdel-Daim, MM; Behl, T; Bungau, SG; Endres, L; Nechifor, AC; Negru, PA; Pasca, B; Radu, AF; Stoicescu, M; Tit, DM; Vesa, CM	1
Szigeti, J	1
Chaturvedi, N; Chauhan, P; Karthic, A; Kesarwani, V; Kushwaha, SK; Singh, RK; Yadav, BS; Yadav, PK	1
Majewska, A; Smyk, JM	1
Hanai, Y; Ishii, Y; Mabuchi, T; Matsuo, K; Miyazaki, T; Nishimura, K; Nishizawa, K; Ohashi, H; Tateda, K; Uekusa, S; Yoshio, T; Yoshizawa, S	1
Ishii, H; Kimura, H; Kurai, D; Sada, M; Saraya, T; Shirai, T; Sunagawa, S	1
El-Hajjaji, F; Katin, KP; Kaya, S; Kochaev, AI; Maslov, MM	1
Li, Q; Liu, W; Wang, C; Wang, S; Xin, Y	1
Kanda, T; Moriyama, M; Okamoto, H; Sasaki-Tanaka, R; Shibata, T	1
Abdallah, IA; Abdelaziz, MA; Bedair, A; Danielson, ND; Elshafeey, AH; Hammad, SF; Mansour, FR	1
Bazram, A; Farshidi, H; Fathalipour, M; Gharibzadeh, A; Hassaniazad, M; Khalili, E; Noormandi, A	1
Ahmed, GY; Al-Jamea, LH; Alhumaid, S; Almahmoud, S; Barry, M; Dhama, K; Khan, A; Layqah, L; Mohaini, MA; Mutair, AA; Rabaan, AA; Shamou, J; Thoyaja, K; Woodman, A	1
Abdulrahim, Z; Abdulrahman, A; Aljawder, D; Almahroos, A; Alnashaba, F; AlQahtani, M; Alsahaf, F; Alshaikh, F; Atkin, SL; Fayyad, MA; Kumar, N; Mohamed, MW; Otoom, S; Saeed, S	1
Aboshabana, R; Belal, F; El Sharkasy, ME; Tolba, MM; Walash, M	1
Sriwijitalai, W; Wiwanitkit, V	1
Abd Allah, FI; Abdelhmaid, A; El-Attar, AMM; Himida, M; Mostafa Elkashlan, A	1
Aoyagi, K; Arakita, K; Banno, S; Doi, Y; Fujisawa, Y; Hase, R; Hattori, H; Ikeda, H; Ikeda, N; Kamio, T; Kasahara, K; Kashizaki, F; Kato, H; Kondo, M; Mitamura, K; Murayama, K; Nakagawa, A; Nishi, K; Ogawa, T; Ohno, Y; Taniguchi, A; Toyama, H	1
Basoglu, OK; Erdem, HA; Gokengin, D; Korkmaz Ekren, P; Ozhan, MH; Sayiner, A; Tasbakan, MI; Tasbakan, S; Yamazhan, T	1
Chen, J; Li, X; Liu, T; Xu, M; Ye, X; Zheng, H	1
Al-Harrasi, A; El Deeb, S; Ibrahim, AE; Sayed, RA; Sharaf, YA	1
Atçalı, T; Caglayan, C; Kandemir, FM; Kara, A; Ulucan, A; Yakut, S	1
Adachi, Y; Matsumura, T; Mineshita, M; Morikawa, M; Moriyama, S; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Takahashi, Y	1
Abdelaal, AH; Abozaid, AA; Ads, AM; Alhijazeen, S; Aziz, JMA; Ghula, S; Hirayama, K; Hung, DT; Huy, NT; Ibrahim, AM; Iiyama, T; Karmally, Z; Kita, K; Kouz, B; Le, TN; Makram, AM; Nakhare, S; Nam, NH; Pancharatnam, RA; Phuong, NQ; Shabouk, MB; Tawfik, GM; Turnage, M	1
Alver, Ö; Bağlayan, Ö; Parlak, C; Ramasami, P	1
Jakab, F; Keserű, GM; Lanszki, Z; Papp, H	1
Mori, N	1
Chang, SP; Hung, SH; Lai, CC; Lan, SH; Lin, WT; Lu, LC	1
Deeb, SE; Ibrahim, AE; Salman, BI; Saraya, RE	1
Kulkarni, P; Padmanabhan, S	1
Epstein, C; Hayden, FG; Kang, LL; Lenk, RP; Oldham-Creamer, C; Stonis, L	1
Akalan, H; Ates, O; Karaarslan, N; Ozbek, H; Sirin, DY; Yilmaz, I	1
Arnuntasupakul, V; Kiertiburanakul, S; Kobpetchyok, W; Surapat, B	1
Fischer, M; Luck, M; Müller, P; Scheidt, HA	1
El Deeb, S; Ibrahim, AE; Sayed, RA; Sharaf, YA	1
Belal, F; El-Awady, M; Elmansi, H; Shabana, RA	1
Abe, H; Afowowe, TO; Urata, S; Yasuda, J; Zadeh, VR	1
Herman, B; Viwattanakulvanid, P; Wong, MC	1
Abdelazim, AH; Hasan, MA; Osman, AO; Ramzy, S	1
Adom, AA; Aguirre-Alvarado, C; Aguirre-Gil, G; Bekker-Méndez, C; Cortes-Vazquez, MA; Cruz-Carbajal, AS; Dehbi, HM; Delgado-Pastelin, L; Escobedo, J; Favari-Perozzi, L; Gastine, S; González, YSP; Hoyo-Vadillo, C; Lowe, D; Mateos, E; Navarro-Gualito, MD; Owen, A; Smith, T; Standing, J; Villegas-Lara, B	1
Furuta, Y; Komeno, T; Morinaga, Y; Nakajima, N; Tani, H	1
Abdelaleem, EA; Abdelfatah, RM; Abdelmoety, RH; Abdelmomen, EH; Emam, AA	1
Allen, DM; Blasiak, A; Chai, LYA; Chan, CEZ; Chow, EK; Chye, H; Ho, D; Hooi, L; Lye, DCB; Remus, A; Seah, SGK; Tan, GG; Tan, SB; Truong, ATL; Wang, P; You, K	1
Charoenpong, L; Chokephaibulkit, K; Copeland, KK; Mahasirimongkol, S; Manosuthi, W; Niyomnaitham, S; Owen, A; Rattanasompattikul, M; Sirijatuphat, R; Wichukchinda, N	1
Egawa, K; Fujii, H; Fukushi, S; Furuta, Y; Harada, S; Komeno, T; Kurosu, T; Lim, CK; Maeki, T; Morikawa, S; Nakajima, N; Saijo, M; Shimojima, M; Takayama-Ito, M; Tani, H; Taniguchi, S; Uda, A; Yamada, S; Yoshikawa, T	1
Behillil, S; Chapon, C; Contreras, V; de Lamballerie, X; Delache, B; Dereuddre-Bosquet, N; Desjardins, D; Guedj, J; Ho Tsong Fang, R; Kahlaoui, N; Le Grand, R; Lemaitre, J; Lingas, G; Ludot, C; Maisonnasse, P; Malvy, D; Marlin, R; Naninck, T; Nougairede, A; Pascal, Q; Pizzorno, A; Relouzat, F; Roques, P; Rosa Calatrava, M; Solas, C; Terrier, O; van der Werf, S	1
Balboni, A; Campos, JAS; Cilla, D; Finberg, R; Golan, Y; Gonzales-Rojas, Y; Hanabergh, R; Lopez, R; Woolson, R	1
Dube, A; Dyawanapelly, S; Junnuthula, V; Khunt, D; Parikh, S; Patel, R; Solanki, R	1
Abdel-Halim, H; Abdelmalek, SMA; Hajar, M; Hasouneh, L	1
Erk, N; Mehmandoust, M; Soylak, M	1
Itoh, SG; Okumura, H; Tanimoto, S	1
Bergeron, E; Li, J; Ren, N; Wang, F; Wang, J; Wang, S; Xia, H; Yuan, Z; Zhang, B; Zhang, G; Zhao, L	1
Bamford, A; Booth, C; Breuer, J; Cheng, I; Chetty, K; Gonzalez-Granado, LI; Kaliakatsos, M; Klapsa, D; Martin, J	1
Atay, E; Bilir, A; Firat, F; Kundakci, YE	1
Akbaş, N; Altındağ, F; Balcı, S; Bulut, S; Çöllüoğlu, Ç; Süleyman, H; Yavuzer, B	1
Chen, M; Dai, W; Yang, F; Yang, K; Zeng, J	1
Tsuji, M	1
Bailey, KW; Gantla, VR; Gowen, BB; Henkel, G; Hickerson, BT; McCormack, K; Naik, S; Wandersee, L; Westover, JB	1
Furton, KG; Gazioglu, I; Kabir, A; Locatelli, M; Tiris, G	1
Shalhoub, S	1
Bhavsar, PK; Boffito, M; Caneja, C; Cardoso, SW; Conway, F; Crabtree Ramírez, B; Donaldson, GC; Grinsztejn, B; Johnson, MR; Leaper, C; Mann, B; Orton, CM; Pelly, M; Pozniak, A; Riberio, MPD; Ritchie, AI; Samson, A; Santos, BR; Shah, PL; Tana, A; Tonkin, J; Vijayakumar, B; Wiseman, DJ	1
Aisyah Rahmania, T; Azzahra Rahmadhani, C; Harahap, Y	1
Alshammari, A	1
Álvarez, G; Cabrera, G; Cerecetto, H; Couto, M; Echeverría, G; Fuentes, G; Gotopo, L; Pezaroglo, H; Piro, O; Romero, AH; Suescun, L	1
Cain, M; Ly, H	1
Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B	1

Reviews

91 review(s) available for pyrazines and favipiravir

Article	Year
Developing new antiviral agents for influenza treatment: what does the future hold? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jan-01, Volume: 48 Suppl 1 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cyclopentanes; Drug Discovery; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Pyrazines; Recombinant Fusion Proteins; Zanamivir	2009
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral research, 2009, Volume: 82, Issue:3 Topics: Amides; Animals; Antiviral Agents; Nucleosides; Pyrazines; RNA Virus Infections; RNA Viruses; RNA-Dependent RNA Polymerase; Viral Proteins	2009
Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral research, 2012, Volume: 96, Issue:3 Topics: Amides; Animals; Antibodies, Viral; Antiviral Agents; Cross Reactions; Host-Pathogen Interactions; Humans; Immunomodulation; Influenza A virus; Orthomyxoviridae Infections; Pyrazines; Receptors, Cell Surface; Viral Matrix Proteins; Virus Attachment; Virus Internalization; Virus Replication	2012
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research, 2013, Volume: 100, Issue:2 Topics: Amides; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Pyrazines; RNA Viruses; United States	2013
Antiviral therapy for human rabies. Antiviral therapy, 2015, Volume: 20, Issue:1 Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Central Nervous System; Combined Modality Therapy; Contraindications; Humans; Immunologic Factors; Minocycline; Molecular Targeted Therapy; Neuroprotective Agents; Pyrazines; Rabies; Rabies virus; RNA, Small Interfering; Virus Assembly; Virus Release	2015
Current status of chemically synthesized inhibitors of Ebola virus. Recent patents on anti-infective drug discovery, 2014, Volume: 9, Issue:2 Topics: Adenine; Adenosine; Amides; Antiviral Agents; Cytosine; Drug Discovery; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Organophosphonates; Patents as Topic; Purine Nucleosides; Pyrazines; Pyrrolidines	2014
Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:7 Topics: Acute Lung Injury; Adult; Amides; Antiviral Agents; Female; Hemorrhagic Fever, Ebola; Humans; Nursing Assistants; Occupational Diseases; Patient Isolation; Plasma; Pyrazines; Respiratory Distress Syndrome; Spain; Superinfection; Transfusion Reaction; Viral Load	2015
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Amides; Amidines; Androstenes; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral Agents; Benzofurans; Cytosine; Disease Models, Animal; Disease Outbreaks; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Immune Sera; Organophosphonates; Pyrazines; RNA, Small Interfering; Stilbenes; Virus Replication	2015
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. Expert review of anti-infective therapy, 2015, Volume: 13, Issue:11 Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir	2015
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clinical pharmacokinetics, 2016, Volume: 55, Issue:8 Topics: Adenine; Adenosine; Amides; Animals; Antiviral Agents; Disease Outbreaks; Ebolavirus; Healthy Volunteers; Hemorrhagic Fever, Ebola; Humans; Models, Animal; Purine Nucleosides; Pyrazines; Pyrrolidines	2016
Current and novel antiviral strategies for influenza infection. Current opinion in virology, 2016, Volume: 18 Topics: Amides; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Nucleoproteins; Pyrazines; Respiratory Tract Infections; Virus Replication	2016
[Favipiravir, a new concept of antiviral drug against influenza viruses]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2017, Volume: 30, Issue:2 Topics: Amides; Animals; Antiviral Agents; Humans; Influenza, Human; Orthomyxoviridae; Pyrazines	2017
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2017, Volume: 93, Issue:7 Topics: Amides; Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Pyrazines; Viruses	2017
The path towards effective antivirals against rabies. Vaccine, 2019, 08-02, Volume: 37, Issue:33 Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Drug Repositioning; Humans; Post-Exposure Prophylaxis; Pyrazines; Pyrrolidines; Rabies; Rabies virus	2019
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research, 2018, Volume: 153 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Humans; Pyrazines; RNA Virus Infections; RNA Viruses; Treatment Outcome	2018
Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:10 Topics: Aged, 80 and over; Amides; Animals; Antiviral Agents; Bunyaviridae Infections; China; Female; Humans; Japan; Male; Mice; Mice, Knockout; Middle Aged; Mortality; Phlebovirus; Pyrazines; Republic of Korea; Syndrome; Thrombocytopenia	2018
Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC infectious diseases, 2019, May-02, Volume: 19, Issue:1 Topics: Amides; Amodiaquine; Antibodies, Monoclonal; Antiviral Agents; Artemisinins; Databases, Factual; Drug Combinations; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Pyrazines; Randomized Controlled Trials as Topic	2019
Antivirals targeting the polymerase complex of influenza viruses. Antiviral research, 2019, Volume: 169 Topics: Amides; Antiviral Agents; Dibenzothiepins; DNA-Directed RNA Polymerases; Drug Combinations; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Influenza B virus; Morpholines; Neuraminidase; Orthomyxoviridae; Oseltamivir; Oxazines; Pyrazines; Pyridines; Pyridones; Serine Endopeptidases; Thiepins; Triazines	2019
Progress on the Prevention and Treatment of Hantavirus Disease. Viruses, 2019, 07-04, Volume: 11, Issue:7 Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines	2019
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry, an Asian journal, 2019, Nov-18, Volume: 14, Issue:22 Topics: Adenine; Adenosine; Alanine; Amides; Antiviral Agents; Base Pairing; Ebolavirus; Guanine; Hemorrhagic Fevers, Viral; Humans; Nucleotides; Phosphoric Acids; Pyrazines; Triazines	2019
Influenza management with new therapies. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:3 Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir	2020
Next-generation direct-acting influenza therapeutics. Translational research : the journal of laboratory and clinical medicine, 2020, Volume: 220 Topics: Amides; Antibodies, Neutralizing; Antiviral Agents; Cytidine; Dibenzothiepins; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Morpholines; Neuraminidase; Oxazines; Pyrazines; Pyridines; Pyridones; Ribonucleosides; RNA-Dependent RNA Polymerase; Thiepins; Triazines; Virus Replication	2020
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics, 2020, Volume: 209 Topics: Amides; Animals; Antiviral Agents; Humans; Influenza, Human; Pyrazines; RNA Virus Infections	2020
Clinical trial analysis of 2019-nCoV therapy registered in China. Journal of medical virology, 2020, Volume: 92, Issue:6 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Management; Disease Outbreaks; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Pyrazines; SARS-CoV-2	2020
Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harbor perspectives in medicine, 2021, 05-03, Volume: 11, Issue:5 Topics: Amides; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Humans; Influenza, Human; Morpholines; Orthomyxoviridae; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; RNA-Dependent RNA Polymerase; Triazines; Virus Replication	2021
Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT: pharmacometrics & systems pharmacology, 2020, Volume: 9, Issue:5 Topics: Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhagic Fever, Ebola; Humans; Models, Theoretical; Pyrazines	2020
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2 Topics: Acetaminophen; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Coronavirus Infections; COVID-19 Drug Treatment; Drug Interactions; Humans; Pyrazines	2020
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020, May-12, Volume: 323, Issue:18 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment	2020
Antiviral treatment of COVID-19 Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles	2020
Treatment options for COVID-19: The reality and challenges. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Teicoplanin	2020
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:12 Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines	2020
Pharmacotherapy in COVID-19; A narrative review for emergency providers. The American journal of emergency medicine, 2020, Volume: 38, Issue:7 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Emergency Service, Hospital; Humans; Hydroxychloroquine; Interleukin-6; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2	2020
Treatment of SARS-CoV-2: How far have we reached? Drug discoveries & therapeutics, 2020, May-06, Volume: 14, Issue:2 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2	2020
Medical treatment options for COVID-19. European heart journal. Acute cardiovascular care, 2020, Volume: 9, Issue:3 Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Recombinant Proteins; RNA, Viral; SARS-CoV-2	2020
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 07-06, Volume: 192, Issue:27 Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2	2020
Coronavirus Disease 2019: Clinical Review. Acta medica portuguesa, 2020, Jul-01, Volume: 33, Issue:7-8 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment	2020
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus research, 2020, Volume: 286 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis	2020
Uric Acid Elevation by Favipiravir, an Antiviral Drug. The Tohoku journal of experimental medicine, 2020, Volume: 251, Issue:2 Topics: Aldehyde Oxidase; Amides; Antiviral Agents; Biotransformation; Coronavirus Infections; COVID-19; Drug Interactions; Humans; Hyperuricemia; Kidney; Kidney Diseases; Molecular Structure; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pandemics; Pneumonia, Viral; Pyrazines; Uric Acid; Xanthine Oxidase	2020
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. Virus research, 2020, Volume: 286 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin	2020
Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrobial agents and chemotherapy, 2020, 08-20, Volume: 64, Issue:9 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome	2020
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS discovery : advancing life sciences R & D, 2020, Volume: 25, Issue:10 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Middle East Respiratory Syndrome Coronavirus; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2; Viral Proteins; Virus Replication	2020
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Journal of infection and public health, 2020, Volume: 13, Issue:10 Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2	2020
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities. The Journal of allergy and clinical immunology, 2020, Volume: 146, Issue:4 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Hypersensitivity; Humans; Immunity, Innate; Immunologic Factors; Indoles; Infliximab; Interleukin 1 Receptor Antagonist Protein; Nitriles; Pandemics; Pneumonia, Viral; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2; Severity of Illness Index	2020
Advances and challenges in the prevention and treatment of COVID-19. International journal of medical sciences, 2020, Volume: 17, Issue:12 Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclophilins; Drug Development; Drug Repositioning; Drugs, Chinese Herbal; Endocytosis; Humans; Immune Sera; Interferon Inducers; Nucleic Acid Synthesis Inhibitors; Pandemics; Pneumonia, Viral; Pyrazines; Resveratrol; SARS-CoV-2; Viral Vaccines	2020
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. Journal of infection and public health, 2020, Volume: 13, Issue:9 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2	2020
Potential strategies for combating COVID-19. Archives of virology, 2020, Volume: 165, Issue:11 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines	2020
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. Clinical rheumatology, 2020, Volume: 39, Issue:11 Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed	2020
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh medical journal : MMJ, 2020, Volume: 29, Issue:3 Topics: Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Treatment Outcome	2020
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular cell, 2020, 09-03, Volume: 79, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication	2020
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology journal, 2020, 09-24, Volume: 17, Issue:1 Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Databases, Factual; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Standard of Care; Treatment Outcome	2020
Current treatment of COVID-19 in renal patients: hope or hype? Internal and emergency medicine, 2020, Volume: 15, Issue:8 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir	2020
COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Virologica Sinica, 2020, Volume: 35, Issue:6 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Repositioning; Humans; Immunization, Passive; Medicine, Chinese Traditional; Pandemics; Pyrazines; SARS-CoV-2; World Health Organization	2020
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO molecular medicine, 2021, 01-11, Volume: 13, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication	2021
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem : a European journal of chemical biology, 2021, 03-16, Volume: 22, Issue:6 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2	2021
Favipiravir use for SARS CoV-2 infection. Pharmacological reports : PR, 2020, Volume: 72, Issue:6 Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome	2020
Emerging treatment strategies for COVID-19 infection. Clinical and experimental medicine, 2021, Volume: 21, Issue:2 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Humans; Hydroxychloroquine; Immunization, Passive; Palliative Care; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Role of favipiravir in the treatment of COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 102 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pyrazines; SARS-CoV-2	2021
Favipiravir and COVID-19: A Simplified Summary. Drug research, 2021, Volume: 71, Issue:3 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Humans; Mutagenesis; Pyrazines; RNA, Viral; SARS-CoV-2; Treatment Outcome	2021
An effective drug against COVID-19: reality or dream? Expert review of respiratory medicine, 2021, Volume: 15, Issue:4 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Development; Humans; Pandemics; Pyrazines	2021
One year update on the COVID-19 pandemic: Where are we now? Acta tropica, 2021, Volume: 214 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses	2021
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. Molecules (Basel, Switzerland), 2020, Dec-03, Volume: 25, Issue:23 Topics: Amides; Antiviral Agents; Coronavirus; Drug Design; Enzyme Inhibitors; Flavivirus; Hepacivirus; Humans; Pyrazines; RNA Virus Infections; RNA Viruses; RNA-Dependent RNA Polymerase; Small Molecule Libraries	2020
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Advances in chronic kidney disease, 2020, Volume: 27, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2	2020
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. SLAS discovery : advancing life sciences R & D, 2021, Volume: 26, Issue:3 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Humans; Immunization, Passive; Pyrazines; SARS-CoV-2; Viral Proteins	2021
Possible treatment and strategies for COVID-19: review and assessment. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:23 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles	2020
A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Expert review of anti-infective therapy, 2021, Volume: 19, Issue:8 Topics: Adult; Amides; Antiviral Agents; COVID-19 Drug Treatment; Female; Humans; Pregnancy; Pyrazines	2021
Antiviral treatment in COVID-19: which is the most promising?-a narrative review. Annals of palliative medicine, 2021, Volume: 10, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles	2021
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. Journal of medical virology, 2021, Volume: 93, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2	2021
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert opinion on therapeutic patents, 2021, Volume: 31, Issue:4 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Repositioning; Humans; Hydroxylamines; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2021
The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. International journal of environmental research and public health, 2021, 01-22, Volume: 18, Issue:3 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Pandemics; Pyrazines	2021
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. Archives of microbiology, 2021, Volume: 203, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2	2021
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] Recenti progressi in medicina, 2021, Volume: 112, Issue:3 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Lopinavir; Mesenchymal Stem Cell Transplantation; Pandemics; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Treatment Outcome; Uncertainty	2021
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert review of anti-infective therapy, 2021, Volume: 19, Issue:10 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate	2021
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 2021, 04-13, Volume: 13, Issue:4 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Hemorrhagic Fever, Ebola; Humans; Middle East Respiratory Syndrome Coronavirus; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2; Virus Replication; Zika Virus; Zika Virus Infection	2021
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific reports, 2021, 05-26, Volume: 11, Issue:1 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Intensive Care Units; Pyrazines; SARS-CoV-2; Survival Analysis; Treatment Outcome; Viral Load	2021
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. Epilepsy research, 2021, Volume: 174 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2	2021
Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC infectious diseases, 2021, May-27, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome; Viral Load; Young Adult	2021
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2021, Volume: 54, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine	2021
Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:2 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pyrazines; SARS-CoV-2	2022
Effectiveness of favipiravir in COVID-19: a live systematic review. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Young Adult	2021
Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far. Current drug research reviews, 2022, Volume: 14, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome	2022
Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2022, Volume: 166, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; COVID-19 Drug Treatment; Humans; Pyrazines; RNA, Viral; SARS-CoV-2	2022
Evaluation of favipiravir in the treatment of COVID-19 based on the real-world. Expert review of anti-infective therapy, 2022, Volume: 20, Issue:4 Topics: Amides; COVID-19 Drug Treatment; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome	2022
Future of antivirals in COVID-19: The case of favipiravir. International immunopharmacology, 2022, Volume: 103 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome	2022
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Environmental and molecular mutagenesis, 2022, Volume: 63, Issue:1 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2	2022
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. Pharmacology & therapeutics, 2022, Volume: 235 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; COVID-19 Testing; Cytomegalovirus Infections; Humans; Influenza, Human; Pyrazines; SARS-CoV-2	2022
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2	2022
Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp). Molecules (Basel, Switzerland), 2022, Jan-26, Volume: 27, Issue:3 Topics: Adenosine Monophosphate; Alanine; Amides; Catalytic Domain; Computational Biology; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines; Pyrimidines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Triazoles; Virus Replication	2022
The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 120 Topics: Amides; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperuricemia; Pyrazines; SARS-CoV-2; Treatment Outcome	2022
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert review of clinical pharmacology, 2022, Volume: 15, Issue:6 Topics: Amides; COVID-19 Drug Treatment; Humans; Pyrazines; Randomized Controlled Trials as Topic	2022
State-of-the-Art Molecular Dynamics Simulation Studies of RNA-Dependent RNA Polymerase of SARS-CoV-2. International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18 Topics: Adenosine Triphosphate; Amides; Antiviral Agents; COVID-19; Humans; Ligands; Lysine; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines; RNA; RNA-Dependent RNA Polymerase; SARS-CoV-2	2022
A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients. Journal of infection in developing countries, 2022, 09-30, Volume: 16, Issue:9 Topics: Amides; Chloroquine; COVID-19 Drug Treatment; Humans; Lopinavir; Network Meta-Analysis; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome	2022

Trials

39 trial(s) available for pyrazines and favipiravir

Article	Year
Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. British journal of clinical pharmacology, 2015, Volume: 80, Issue:5 Topics: Acetaminophen; Adult; Amides; Analgesics, Non-Narcotic; Antiviral Agents; Drug Interactions; Female; Humans; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Pyrazines; Young Adult	2015
Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:10 Topics: Adult; Amides; Antiviral Agents; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Male; Pyrazines; Young Adult	2015
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS medicine, 2016, Volume: 13, Issue:3 Topics: Adolescent; Adult; Amides; Antiviral Agents; Child; Child, Preschool; Ebolavirus; Feasibility Studies; Female; Guinea; Hemorrhagic Fever, Ebola; Historically Controlled Study; Humans; Infant; Male; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Therapies, Investigational; Treatment Outcome; Viral Load; Young Adult	2016
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. The New England journal of medicine, 2016, 10-13, Volume: 375, Issue:15 Topics: Adolescent; Adult; Africa, Western; Amides; Antibodies, Monoclonal; Bayes Theorem; Child; Combined Modality Therapy; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Humans; Kaplan-Meier Estimate; Male; Polymerase Chain Reaction; Pyrazines; Treatment Outcome; United States; Viral Load	2016
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Child; Child, Preschool; Ebolavirus; Female; Guinea; Hemorrhagic Fever, Ebola; Humans; Male; Middle Aged; Pyrazines; Young Adult	2017
Use of Favipiravir to Treat Lassa Virus Infection in Macaques. Emerging infectious diseases, 2018, Volume: 24, Issue:9 Topics: Amides; Animals; Antiviral Agents; Female; Injections, Subcutaneous; Lassa Fever; Lassa virus; Macaca; Monkey Diseases; Pyrazines; Random Allocation; Treatment Outcome	2018
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clinical and translational science, 2020, Volume: 13, Issue:5 Topics: Adult; Aged; Amides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intubation, Gastrointestinal; Male; Pandemics; Pneumonia, Viral; Pyrazines; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Suspensions; Tablets; Treatment Outcome	2020
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled Trials, 2020, Jun-05, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; RNA, Viral; SARS-CoV-2; Treatment Outcome; Young Adult	2020
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrobial agents and chemotherapy, 2020, 11-17, Volume: 64, Issue:12 Topics: Adolescent; Adult; Amides; Antiviral Agents; Asymptomatic Diseases; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hyperuricemia; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Random Allocation; SARS-CoV-2; Secondary Prevention; Severity of Illness Index; Time-to-Treatment; Treatment Outcome; Viral Load	2020
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R Trials, 2020, Oct-13, Volume: 21, Issue:1 Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Tolerance; Feasibility Studies; France; Hospitalization; Humans; Hydroxychloroquine; Imatinib Mesylate; Luxembourg; Outpatients; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Risk Reduction Behavior; SARS-CoV-2; Telmisartan; Therapies, Investigational; Treatment Outcome	2020
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, Oct-13, Volume: 21, Issue:1 Topics: Amides; Antiviral Agents; Australia; Betacoronavirus; Biomarkers; Clinical Protocols; Coronavirus Infections; COVID-19; Female; Hospitalization; Humans; Male; Pandemics; Placebos; Pneumonia, Viral; Pyrazines; Safety; SARS-CoV-2; Treatment Outcome	2020
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, Oct-27, Volume: 21, Issue:1 Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Interferons; Iran; Lopinavir; Male; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Viral Load	2020
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Feb-01, Volume: 157 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Dibenzothiepins; Drug Monitoring; Female; Humans; Inhibitory Concentration 50; Male; Middle Aged; Morpholines; Pyrazines; Pyridones; SARS-CoV-2; Symptom Assessment; Treatment Outcome; Triazines; Viral Load	2021
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, Oct-31, Volume: 21, Issue:1 Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Inpatients; Male; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Saudi Arabia; Time Factors; Treatment Outcome	2020
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 102 Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Interferon beta-1b; Male; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 103 Topics: Adolescent; Adult; Aged; Amides; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2; Young Adult	2021
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133 Topics: Adult; Aged; Aged, 80 and over; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Lung; Male; Middle Aged; Models, Immunological; Pyrazines; Receptors, Interleukin-6; Respiration, Artificial; Sample Size; SARS-CoV-2; Treatment Outcome	2021
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Archives of virology, 2021, Volume: 166, Issue:3 Topics: Adult; Amides; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Length of Stay; Male; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	2021
Bioequivalence study of two favipiravir tablet formulations in healthy male subjects. International journal of clinical pharmacology and therapeutics, 2021, Volume: 59, Issue:5 Topics: Amides; Antiviral Agents; Area Under Curve; COVID-19 Drug Treatment; Cross-Over Studies; Healthy Volunteers; Humans; Male; Pyrazines; SARS-CoV-2; Tablets; Therapeutic Equivalency	2021
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, Mar-08, Volume: 22, Issue:1 Topics: Ambulatory Care; Amides; Antiviral Agents; Clinical Trials, Phase II as Topic; COVID-19 Drug Treatment; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Humans; Lopinavir; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; United Kingdom; Viral Load	2021
Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Scientific reports, 2021, 03-31, Volume: 11, Issue:1 Topics: Adult; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Humans; Hydroxychloroquine; Male; Middle Aged; Oseltamivir; Pyrazines; Treatment Outcome	2021
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19. BMJ open, 2021, 04-14, Volume: 11, Issue:4 Topics: Adult; Amides; COVID-19 Drug Treatment; Female; Humans; Male; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome	2021
Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome. Signal transduction and targeted therapy, 2021, 04-16, Volume: 6, Issue:1 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Phlebovirus; Prospective Studies; Pyrazines; Severe Fever with Thrombocytopenia Syndrome; Single-Blind Method	2021
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. International immunopharmacology, 2021, Volume: 97 Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Patient Discharge; Pyrazines; Reinfection; RNA, Viral; SARS-CoV-2; Treatment Outcome	2021
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC infectious diseases, 2021, May-04, Volume: 21, Issue:1 Topics: Aged; Amides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Ivermectin; Male; Middle Aged; Pneumonia, Viral; Prospective Studies; Pyrazines; Single-Blind Method; Treatment Outcome	2021
Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:11 Topics: Acute Kidney Injury; Adenosine Monophosphate; Adolescent; Alanine; Amides; Child; COVID-19; COVID-19 Drug Treatment; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Pyrazines; Renal Elimination; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Treatment Outcome	2021
Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:9 Topics: Amides; Antiviral Agents; China; COVID-19; Europe; Genomics; Humans; Japan; Male; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. International immunopharmacology, 2021, Volume: 99 Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cyclosporine; Dexamethasone; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome; Young Adult	2021
Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome. EBioMedicine, 2021, Volume: 72 Topics: Aged; Amides; Antiviral Agents; Female; Humans; Male; Middle Aged; Pyrazines; Severe Fever with Thrombocytopenia Syndrome; Treatment Outcome; Viral Load	2021
Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-24, Volume: 75, Issue:1 Topics: Amides; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hypoxia; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome	2022
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. European journal of pharmacology, 2022, Jan-05, Volume: 914 Topics: Adenosine Monophosphate; Alanine; Amides; Antioxidants; Antiviral Agents; Biomarkers; COVID-19; COVID-19 Drug Treatment; Drug Monitoring; Female; Hemoglobins; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Patient Discharge; Pyrazines; Quercetin; Respiratory Rate	2022
Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:4 Topics: Adult; Amides; COVID-19 Drug Treatment; Double-Blind Method; Humans; Male; Pyrazines; Treatment Outcome	2022
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial. Journal of medical virology, 2022, Volume: 94, Issue:7 Topics: Amides; COVID-19 Drug Treatment; Humans; Interferon-beta; Iran; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2	2022
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Scientific reports, 2022, 03-23, Volume: 12, Issue:1 Topics: Amides; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pilot Projects; Pyrazines; SARS-CoV-2	2022
Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. Japanese journal of radiology, 2022, Volume: 40, Issue:8 Topics: Algorithms; Amides; Artificial Intelligence; COVID-19; Humans; Lung; Prospective Studies; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed	2022
Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. The Journal of infectious diseases, 2022, 11-11, Volume: 226, Issue:10 Topics: Adult; Antiviral Agents; Double-Blind Method; Fever; Humans; Influenza, Human; Pyrazines; RNA; Treatment Outcome	2022
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). Trials, 2022, Jul-22, Volume: 23, Issue:1 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Nitro Compounds; Pyrazines; SARS-CoV-2; Secondary Prevention; Thiazoles; Treatment Outcome	2022
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. Emerging microbes & infections, 2022, Volume: 11, Issue:1 Topics: Adult; Amides; Antiviral Agents; COVID-19 Drug Treatment; Female; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome	2022
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. The Lancet. Respiratory medicine, 2023, Volume: 11, Issue:5 Topics: Adult; Aged; COVID-19; Humans; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome	2023

Other Studies

371 other study(ies) available for pyrazines and favipiravir

Article	Year
In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:4 Topics: Amides; Animals; Antiviral Agents; Cell Line; Drug Screening Assays, Antitumor; Humans; Influenza, Human; Lung; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Orthomyxoviridae; Pyrazines; Viruses	2002
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antiviral chemistry & chemotherapy, 2003, Volume: 14, Issue:5 Topics: Acetamides; Amides; Animals; Antiviral Agents; Drug Evaluation, Preclinical; Influenza A virus; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate; Time Factors	2003
Mechanism of action of T-705 against influenza virus. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:3 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; DNA; DNA-Directed RNA Polymerases; IMP Dehydrogenase; Orthomyxoviridae; Pyrazines; RNA	2005
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Amides; Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Oxygen; Pyrazines; Survival Analysis; Virus Replication	2007
Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Cricetinae; Disease Models, Animal; Female; Humans; Mesocricetus; Pyrazines; Treatment Outcome; Vero Cells; Yellow Fever; Yellow fever virus	2007
In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Amides; Animals; Antiviral Agents; Arenaviridae Infections; Bunyaviridae Infections; Cell Line; Cricetinae; Haplorhini; Liver; Mice; Pyrazines; Ribavirin; Viral Load	2007
Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral research, 2008, Volume: 80, Issue:3 Topics: Administration, Oral; Amides; Animals; Brain; Cricetinae; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Mesocricetus; Mice; Mice, Inbred C57BL; Pyrazines; West Nile Fever; West Nile virus	2008
Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Amides; Animals; Antiviral Agents; Cricetinae; Drug Administration Schedule; Molecular Structure; Pyrazines; Yellow Fever; Yellow fever virus	2009
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS one, 2008, Volume: 3, Issue:11 Topics: Absorption; Administration, Oral; Alanine Transaminase; Amides; Animals; Arenaviridae Infections; Aspartate Aminotransferases; Cricetinae; Disease Models, Animal; Disease Progression; Female; Hemorrhagic Fevers, Viral; Interferon Type I; Liver Diseases; Mesocricetus; Pichinde virus; Pyrazines; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load	2008
Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral research, 2009, Volume: 82, Issue:3 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Body Weight; Chlorocebus aethiops; Disease Models, Animal; Encephalomyelitis, Western Equine; Mice; Mice, Inbred C57BL; Pyrazines; Serum; Survival Analysis; Vero Cells	2009
Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:4 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chromatography, High Pressure Liquid; Cytosol; Dogs; Guanosine Triphosphate; Influenza A Virus, H5N1 Subtype; Pyrazines; Spectrophotometry, Ultraviolet	2009
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral research, 2010, Volume: 86, Issue:2 Topics: Amides; Animals; Antiviral Agents; Bunyaviridae Infections; Chlorocebus aethiops; Cricetinae; Disease Models, Animal; Female; Liver; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Nucleosides; Pyrazines; Serum; Survival Analysis; Treatment Outcome; Vero Cells; Viral Load	2010
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Amides; Animals; Antiviral Agents; Cell Line; Drug Combinations; Drug Interactions; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrazines	2010
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America, 2010, Jan-12, Volume: 107, Issue:2 Topics: Aged; Amides; Animals; Antiviral Agents; Cell Line; Child; DNA Replication; DNA-Directed DNA Polymerase; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kidney; Kinetics; Lung; Oseltamivir; Pyrazines; Ribavirin	2010
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Amides; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Humans; In Vitro Techniques; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Pyrazines; Swine; Viral Plaque Assay; Virus Replication	2010
T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:2 Topics: Amides; Animals; Antiviral Agents; Arenaviruses, New World; Cell Line; Chlorocebus aethiops; Humans; Junin virus; Lymphocytic choriomeningitis virus; Microbial Sensitivity Tests; Pyrazines; Ribavirin; Vero Cells; Virus Replication	2011
Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antiviral chemistry & chemotherapy, 2011, May-12, Volume: 21, Issue:5 Topics: Amides; Animals; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Microbial Sensitivity Tests; Orthohantavirus; Pyrazines; Vero Cells; Virus Replication	2011
Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS neglected tropical diseases, 2011, Volume: 5, Issue:10 Topics: Amides; Animals; Antiviral Agents; Arenavirus; Disease Models, Animal; Guinea Pigs; Hemorrhagic Fever, American; Humans; Lethal Dose 50; Male; Molecular Sequence Data; Pyrazines; RNA, Viral; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome	2011
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral research, 2012, Volume: 94, Issue:1 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; California; Cyclopentanes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Pandemics; Pyrazines	2012
Favipiravir (T-705) inhibits in vitro norovirus replication. Biochemical and biophysical research communications, 2012, Aug-10, Volume: 424, Issue:4 Topics: Amides; Animals; Cell Line; Mice; Norovirus; Pyrazines; RNA, Viral; Virus Replication	2012
T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. Journal of virology, 2013, Volume: 87, Issue:7 Topics: Amides; Analysis of Variance; Animals; Antiviral Agents; Dogs; Drug Discovery; In Vitro Techniques; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mutagenesis; Orthomyxoviridae Infections; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction	2013
Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10 Topics: Amides; Animals; Antiviral Agents; Cricetinae; Female; Hantavirus Pulmonary Syndrome; Orthohantavirus; Pyrazines; Sin Nombre virus; Virus Replication	2013
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PloS one, 2013, Volume: 8, Issue:7 Topics: Amides; Animals; Antimetabolites; Antiviral Agents; Base Pair Mismatch; Base Pairing; DNA-Directed DNA Polymerase; Humans; Influenza A virus; Polyphosphates; Pyrazines; Ribavirin; Sf9 Cells; Spodoptera; Substrate Specificity	2013
Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Molecular pharmacology, 2013, Volume: 84, Issue:4 Topics: Amides; Animals; Antiviral Agents; Crystallography, X-Ray; Dogs; HEK293 Cells; Humans; Hypoxanthine Phosphoribosyltransferase; Madin Darby Canine Kidney Cells; Pyrazines	2013
Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11 Topics: Adenosine Triphosphate; Amides; Animals; Antiviral Agents; Binding, Competitive; Cytidine Triphosphate; Dogs; Enzyme Assays; Guanosine Triphosphate; Influenza A Virus, H1N1 Subtype; Kinetics; Madin Darby Canine Kidney Cells; Protein Binding; Pyrazines; RNA-Dependent RNA Polymerase; RNA, Viral; Uridine Triphosphate; Viral Proteins	2013
Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antiviral chemistry & chemotherapy, 2014, Dec-16, Volume: 23, Issue:6 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrazines; Reassortant Viruses	2014
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Archives of virology, 2014, Volume: 159, Issue:6 Topics: Amides; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Drug Synergism; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Oseltamivir; Pyrazines	2014
Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS neglected tropical diseases, 2013, Volume: 7, Issue:12 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Disease Models, Animal; Guinea Pigs; Hemorrhagic Fever, American; Injections, Intraperitoneal; Junin virus; Male; Plasma; Pyrazines; Survival Analysis; Viremia	2013
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral research, 2014, Volume: 104 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Disease Models, Animal; Ebolavirus; Hemorrhagic Fever, Ebola; Mice; Mice, Knockout; Pyrazines	2014
Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral research, 2014, Volume: 104 Topics: Amides; Animals; Antiviral Agents; Cell Line; Central Nervous System Viral Diseases; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Microbial Sensitivity Tests; Pyrazines; Rift Valley Fever; Rift Valley fever virus; Viral Load	2014
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral research, 2014, Volume: 105 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Ebolavirus; Hemorrhagic Fever, Ebola; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Survival Analysis; Viral Load; Virus Replication	2014
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS neglected tropical diseases, 2014, Volume: 8, Issue:4 Topics: Amides; Animals; Antiviral Agents; Chemoprevention; Female; Fever; Pyrazines; Rats; Rats, Inbred WF; Rift Valley Fever; Survival Analysis; Treatment Outcome; Weight Loss	2014
Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS neglected tropical diseases, 2014, Volume: 8, Issue:5 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Female; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Indoles; Liver; Male; Mice; Mice, Transgenic; Pyrazines; Receptor, Interferon alpha-beta; Ribavirin; Vero Cells	2014
The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Amides; Antiviral Agents; Cell Line; Cysteine Endopeptidases; Cytidine; Drug Combinations; Drug Synergism; Hepatocytes; Humans; Isoxazoles; Molecular Docking Simulation; Norwalk virus; Papain; Phenylalanine; Pyrazines; Pyrrolidinones; Replicon; RNA-Dependent RNA Polymerase; Valine; Viral Proteins; Virus Replication	2014
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:10 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chikungunya Fever; Chikungunya virus; Cytopathogenic Effect, Viral; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Viral; Mice; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrazines; Reproducibility of Results; Viral Nonstructural Proteins; Virus Replication	2014
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. PloS one, 2014, Volume: 9, Issue:7 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate	2014
Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide. Drug discoveries & therapeutics, 2014, Volume: 8, Issue:3 Topics: Amides; Crystallization; Hydrogen Bonding; Pyrazines	2014
Characterization of susceptibility variants of influenza virus grown in the presence of T-705. Journal of pharmacological sciences, 2014, Volume: 126, Issue:3 Topics: Amides; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Resistance, Viral; Genotype; Influenza A Virus, H1N1 Subtype; Mutation; Pyrazines; Viral Proteins; Virus Replication	2014
Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife, 2014, Oct-21, Volume: 3 Topics: Amides; Animals; Antiviral Agents; Caliciviridae Infections; Cells, Cultured; Feces; Male; Mice, Inbred C57BL; Mutagenesis; Mutation Rate; Norovirus; Pyrazines; Ribavirin; RNA, Viral; Serial Passage; Virus Replication	2014
Clinical trials of Ebola therapies to begin in December. BMJ (Clinical research ed.), 2014, Nov-14, Volume: 349 Topics: Adult; Amides; Blood Transfusion; Child; Clinical Trials as Topic; Guinea; Hemorrhagic Fever, Ebola; Humans; Pyrazines	2014
Dose regimen of favipiravir for Ebola virus disease. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:2 Topics: Adult; Amides; Animals; Antiviral Agents; Computer Simulation; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Mice; Models, Animal; Plasma; Pyrazines	2015
First trials for Ebola treatments announced. Lancet (London, England), 2014, Nov-22, Volume: 384, Issue:9957 Topics: Africa, Western; Amides; Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Female; Follow-Up Studies; Hemorrhagic Fever, Ebola; Humans; Male; Patient Selection; Pyrazines; Risk Assessment; Treatment Outcome	2014
Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet (London, England), 2015, Apr-11, Volume: 385, Issue:9976 Topics: Adult; Amides; Amiodarone; Anti-Infective Agents; Antiviral Agents; Blood Vessels; Critical Care; Fibrin Fibrinogen Degradation Products; Hemorrhagic Fever, Ebola; Humans; Intubation, Intratracheal; Male; Multiple Organ Failure; Patient Isolation; Peptide Fragments; Pulmonary Edema; Pyrazines; Radiography, Thoracic; Renal Insufficiency; Respiratory Insufficiency	2015
Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster medicine and public health preparedness, 2015, Volume: 9, Issue:1 Topics: Amides; Antiviral Agents; Disaster Planning; Drug Approval; Hemorrhagic Fever, Ebola; Humans; Japan; Pyrazines	2015
[Ebola: three experimental clinical trials directed by MSF]. Revue medicale suisse, 2014, Nov-26, Volume: 10, Issue:452 Topics: Africa, Western; Amides; Anti-Infective Agents; Clinical Trials as Topic; Cytosine; France; Health Services Accessibility; Hemorrhagic Fever, Ebola; Humans; International Cooperation; Organophosphonates; Pyrazines; Societies, Medical	2014
Infectious diseases. Ebola drug trials lurch ahead. Science (New York, N.Y.), 2015, Feb-13, Volume: 347, Issue:6223 Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Clinical Trials as Topic; Cytosine; Disease Outbreaks; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Organophosphonates; Pyrazines	2015
Favipiravir for children with Ebola. Lancet (London, England), 2015, Feb-14, Volume: 385, Issue:9968 Topics: Amides; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Dosage Calculations; Hemorrhagic Fever, Ebola; Humans; Infant; Pyrazines	2015
[Ebola and favipiravir: when political preempts scientific communication]. Revue medicale suisse, 2015, Mar-04, Volume: 11, Issue:464 Topics: Amides; Communication; Hemorrhagic Fever, Ebola; Humans; Politics; Pyrazines	2015
Favipiravir--a prophylactic treatment for Ebola contacts? Lancet (London, England), 2015, Jun-13, Volume: 385, Issue:9985 Topics: Amides; Antiviral Agents; Directly Observed Therapy; Hemorrhagic Fever, Ebola; Humans; Post-Exposure Prophylaxis; Pyrazines	2015
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral research, 2015, Volume: 121 Topics: Amides; Animal Structures; Animals; Antiviral Agents; Disease Models, Animal; Female; Hemorrhagic Fevers, Viral; Mesocricetus; Plasma; Pyrazines	2015
Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:9 Topics: Adult; Amides; Antiviral Agents; Ebolavirus; Genome, Viral; Half-Life; Hemorrhagic Fever, Ebola; Humans; Pyrazines; Viral Load; Virus Shedding	2015
Ebola virus dynamics in mice treated with favipiravir. Antiviral research, 2015, Volume: 123 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Mice, Inbred C57BL; Models, Theoretical; Pyrazines; Survival Analysis; Viral Load	2015
Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12 Topics: Amides; Animals; Antiviral Agents; Cell Line, Tumor; Cytidine; DNA-Directed RNA Polymerases; Escherichia coli; Gene Expression Regulation, Viral; Hepatocytes; Host Specificity; Humans; Kinetics; Mice; Norovirus; Pyrazines; Recombinant Proteins; Ribonucleotides; Transcription, Genetic; Viral Proteins; Virus Replication	2015
The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Scientific reports, 2015, Oct-12, Volume: 5 Topics: Amides; Animals; Animals, Outbred Strains; Antibodies, Viral; Antiviral Agents; Drug Administration Schedule; Drug Dosage Calculations; Guinea Pigs; Humans; Immunoglobulin G; Lassa Fever; Lassa virus; Liver; Lung; Male; Pyrazines; Ribavirin; Spleen; Survival Analysis; Viral Load	2015
Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC infectious diseases, 2015, Oct-16, Volume: 15 Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Coinfection; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Lung Diseases, Interstitial; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Pyrazines; Respiration, Artificial; Respiratory Insufficiency; RNA, Viral; Viral Load	2015
Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. The Journal of infectious diseases, 2016, Mar-15, Volume: 213, Issue:6 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Therapy, Combination; Lassa Fever; Mice; Pyrazines; Ribavirin; Vero Cells; Viral Load; Virus Replication	2016
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. The Journal of infectious diseases, 2016, Apr-15, Volume: 213, Issue:8 Topics: Amides; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Mice; Post-Exposure Prophylaxis; Pyrazines; Rabies; Treatment Outcome; Viral Load	2016
Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral research, 2016, Volume: 126 Topics: Amides; Animals; Antiviral Agents; Arenavirus; Chlorocebus aethiops; Cricetinae; Dengue Virus; Disease Models, Animal; Drug Synergism; Female; Guinea Pigs; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, American; Hemorrhagic Fever, Ebola; Hemorrhagic Fevers, Viral; Junin virus; Male; Mesocricetus; Mice; Orthohantavirus; Pyrazines; Ribavirin; RNA Viruses; Vero Cells	2016
Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants. Antimicrobial agents and chemotherapy, 2015, Dec-28, Volume: 60, Issue:3 Topics: Amides; Animals; Caliciviridae Infections; Cytidine; Disease Models, Animal; Feces; Gastroenteritis; Mice; Mice, Knockout; Norovirus; Pyrazines; Receptors, Interferon; Transplant Recipients; Virus Shedding	2015
A 6-Year-Old Child with Severe Ebola Virus Disease: Laboratory-Guided Clinical Care in an Ebola Treatment Center in Guinea. PLoS neglected tropical diseases, 2016, Volume: 10, Issue:3 Topics: Amides; Antiviral Agents; Child; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Limit of Detection; Male; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Viral Load	2016
Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8 Topics: Amides; Animals; Antibodies, Viral; Antiviral Agents; Chlorocebus aethiops; Cricetinae; HEK293 Cells; Humans; Lung; Mesocricetus; Metapneumovirus; Paramyxoviridae Infections; Pyrazines; Respiratory Syncytial Viruses; Vero Cells; Virus Replication	2016
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice. Scientific reports, 2016, 05-25, Volume: 6 Topics: Amides; Animals; Dogs; Drug Therapy, Combination; Female; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrazines	2016
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral research, 2016, Volume: 132 Topics: Amides; Antiviral Agents; Cell Line; Cells, Cultured; Cytopathogenic Effect, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae; Pyrazines; Viral Proteins	2016
In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9 Topics: Amides; Amino Acid Sequence; Animals; Antiviral Agents; Binding Sites; Cell Line, Tumor; Chlorocebus aethiops; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Enterovirus A, Human; Humans; Indoles; Isoxazoles; Itraconazole; Molecular Docking Simulation; Mutation; Myoblasts; Phenols; Phenylalanine; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyrazines; Pyrrolidinones; Sequence Alignment; Sequence Homology, Amino Acid; Suramin; Valine; Vero Cells; Viral Nonstructural Proteins; Virus Replication	2016
Temporary neurocognitive impairment with Ebola virus. Journal of neurology, neurosurgery, and psychiatry, 2016, Volume: 87, Issue:12 Topics: Adult; Amides; Cognitive Dysfunction; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Italy; Male; Middle Aged; Neuropsychological Tests; Pyrazines; Time Factors	2016
Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Nov-15, Volume: 63, Issue:10 Topics: Adolescent; Adult; Amides; Antiviral Agents; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Humans; Kaplan-Meier Estimate; Male; Pyrazines; Retrospective Studies; Sierra Leone; Viral Load; Young Adult	2016
Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 11-15, Volume: 63, Issue:10 Topics: Amides; Disease Outbreaks; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Pyrazines; Randomized Controlled Trials as Topic; Sierra Leone	2016
An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy. Evolution; international journal of organic evolution, 2016, Volume: 70, Issue:11 Topics: Amides; Animals; Anti-Retroviral Agents; Dogs; Drug Resistance, Viral; Evolution, Molecular; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mutation Rate; Polymorphism, Genetic; Pyrazines	2016
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:11 Topics: A549 Cells; Amides; Animals; Antiviral Agents; Chick Embryo; DNA-Directed RNA Polymerases; Dogs; Gene Expression Regulation, Viral; Humans; IMP Dehydrogenase; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation; Pyrazines; Reassortant Viruses; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Structure-Activity Relationship; Viral Proteins; Virus Replication	2016
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor. Ophthalmology, 2016, Volume: 123, Issue:12 Topics: Administration, Oral; Adult; Amides; Atropine; Drug Combinations; Ebolavirus; Eye Infections, Viral; Fluprednisolone; Glucocorticoids; Hemorrhagic Fever, Ebola; Humans; Injections, Intraocular; Iris Diseases; Male; Microscopy, Acoustic; Multimodal Imaging; Mydriatics; Ophthalmic Solutions; Panuveitis; Pigmentation Disorders; Prednisone; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Viral; Survivors; Triamcinolone Acetonide; Vitreous Body	2016
Early and repeated use of plasma for the management of Ebola patients: Reflection around a case. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:1 Topics: Amides; Anti-Bacterial Agents; Blood Component Transfusion; Blood Preservation; Combined Modality Therapy; Disease Management; Freeze Drying; Gastrointestinal Agents; Hemorrhagic Fever, Ebola; Humans; Male; Plasma; Pyrazines; Severity of Illness Index; Young Adult	2017
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PloS one, 2016, Volume: 11, Issue:10 Topics: Amides; Antiviral Agents; Cell Line, Tumor; Cell Survival; Hepacivirus; High-Throughput Nucleotide Sequencing; Humans; Mutation; Pyrazines; RNA, Viral; Sequence Analysis, RNA; Virus Replication	2016
Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir. Journal of virology, 2017, Feb-01, Volume: 91, Issue:3 Topics: Amides; Animals; Animals, Genetically Modified; Antiviral Agents; Bunyaviridae Infections; Cricetinae; Disease Models, Animal; Disease Susceptibility; Genotype; Humans; Models, Biological; Phenotype; Phlebovirus; Pyrazines; STAT2 Transcription Factor	2017
Fate of new three anti-influenza drugs and one prodrug in the water environment. Chemosphere, 2017, Volume: 169 Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Biodegradation, Environmental; Cyclopentanes; Environmental Monitoring; Fresh Water; Guanidines; Half-Life; Humans; Influenza, Human; Japan; Prodrugs; Pyrans; Pyrazines; Rivers; Seasons; Sewage; Sialic Acids; Water Pollutants, Chemical; Zanamivir	2017
Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus research, 2017, 04-02, Volume: 233 Topics: Amides; Animals; Antiviral Agents; Cell Line; Cricetulus; Epithelial Cells; Foot-and-Mouth Disease Virus; Inhibitory Concentration 50; Mutagenesis; Mutagens; Mutation Rate; Pyrazines; Virus Replication	2017
Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. Journal of virology, 2017, 06-15, Volume: 91, Issue:12 Topics: Amides; Amino Acid Motifs; Animals; Antiviral Agents; Chikungunya virus; Chlorocebus aethiops; Drug Resistance, Viral; Enterovirus B, Human; Japan; Lysine; Mice; Microbial Viability; Mutagenesis; Mutation; Pyrazines; RNA-Dependent RNA Polymerase; Vero Cells; Virus Replication	2017
Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral research, 2017, Volume: 143 Topics: Adenosine; Amides; Antiviral Agents; Cell Line; Cytidine; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Humans; Inhibitory Concentration 50; Mitochondria; Mitochondrial Proteins; Nucleosides; Prodrugs; Protein Biosynthesis; Pyrazines; Ribonucleosides; RNA; RNA, Mitochondrial; Sofosbuvir; Structure-Activity Relationship; Transcription Initiation Site; Transcription, Genetic	2017
Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies. Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11 Topics: Amides; Animals; Antiviral Agents; Hemorrhagic Fever, Ebola; Humans; Mice; Pyrazines	2017
Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Antiviral research, 2017, Volume: 143 Topics: Amides; Animals; Antiviral Agents; Bird Diseases; Borna Disease; Borna disease virus; Bornaviridae; Cell Line; Chlorocebus aethiops; Microbial Sensitivity Tests; Pyrazines; Quail; RNA, Viral; Time Factors; Vero Cells; Viral Load; Virus Replication	2017
Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Archives of virology, 2017, Volume: 162, Issue:9 Topics: Amides; Animals; Antiviral Agents; Cell Survival; Chlorocebus aethiops; Dose-Response Relationship, Drug; Molecular Structure; Pyrazines; Vero Cells; Virus Replication; Zika Virus	2017
Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:6 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Confidentiality; Disease Outbreaks; Guinea; Hemorrhagic Fever, Ebola; Humans; Informed Consent; Medical Records; Pyrazines; Research Design	2017
In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin. Antiviral therapy, 2017, Volume: 22, Issue:7 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Synergism; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Pyrazines; Ribavirin; Spatio-Temporal Analysis; Vero Cells; Zika Virus; Zika Virus Infection	2017
Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2018, Volume: 51, Issue:5 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Resistance, Viral; Models, Molecular; Mutation; Poliovirus; Protein Binding; Pyrazines; RNA-Dependent RNA Polymerase; Vero Cells; Viral Proteins; Virus Replication	2018
Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral research, 2017, Volume: 145 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Hemorrhagic Fever, American; Junin virus; Pyrazines; Survival Analysis; Viral Load	2017
Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Mutagenesis; Pyrazines; Vero Cells; West Nile virus	2017
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution. Genome biology and evolution, 2017, 07-01, Volume: 9, Issue:7 Topics: Amides; Animals; Antiviral Agents; Biological Evolution; Cell Line; Dogs; Genetics, Population; Influenza A virus; Mutation Rate; Orthomyxoviridae Infections; Oseltamivir; Pyrazines	2017
Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. BMC infectious diseases, 2017, 08-30, Volume: 17, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Amides; Antibodies, Monoclonal; Ebolavirus; Health Personnel; Hemorrhagic Fever, Ebola; Humans; Indomethacin; Italy; Male; Pericardial Effusion; Pyrazines; Rhabdomyolysis; Sierra Leone	2017
A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses. The Journal of infectious diseases, 2017, 06-15, Volume: 215, Issue:12 Topics: Adult; Amides; Antibodies, Viral; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunity, Cellular; Immunoglobulin Class Switching; Lassa Fever; Lassa virus; Lymphocyte Activation; Male; Pyrazines; Ribavirin; Viremia	2017
Heartland virus infection in hamsters deficient in type I interferon signaling: Protracted disease course ameliorated by favipiravir. Virology, 2017, Volume: 511 Topics: Amides; Animal Structures; Animals; Antiviral Agents; Bunyaviridae Infections; Chemoprevention; Cricetinae; Disease Models, Animal; Inflammation; Interferon Type I; Pyrazines; STAT2 Transcription Factor; Treatment Outcome	2017
Determining Ribavirin's mechanism of action against Lassa virus infection. Scientific reports, 2017, 09-15, Volume: 7, Issue:1 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Lassa Fever; Lassa virus; Mice, Inbred C57BL; Models, Theoretical; Pyrazines; Ribavirin; Treatment Outcome; Viral Load	2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Sep-01, Volume: 65, Issue:5 Topics: Adult; Amides; Antiviral Agents; Humans; Lassa Fever; Lassa virus; Male; Polymerase Chain Reaction; Pyrazines; Ribavirin; RNA, Viral; Togo	2017
Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antiviral research, 2017, Volume: 147 Topics: Amides; Antiviral Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Discovery; Drug Synergism; Genes, Reporter; Green Fluorescent Proteins; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; High-Throughput Screening Assays; Humans; Lethal Dose 50; Pyrazines; Ribavirin; Viral Proteins; Virus Replication	2017
Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antiviral chemistry & chemotherapy, 2017, Volume: 25, Issue:3 Topics: Amides; Amodiaquine; Animals; Antiviral Agents; Bunyaviridae; Bunyaviridae Infections; Cell Line; Chlorocebus aethiops; Fever; Humans; Microbial Sensitivity Tests; Pyrazines; Ribavirin; Thrombocytopenia; Virus Replication	2017
Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:1 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; DNA Replication; Humans; Interferon-alpha; Pyrazines; Ribavirin; Vero Cells; Viral Load; Virus Replication; Zika Virus; Zika Virus Infection	2018
Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. Antiviral therapy, 2018, Volume: 23, Issue:5 Topics: Amides; Antiviral Agents; Critical Illness; Fatal Outcome; Hemofiltration; Humans; Influenza, Human; Intensive Care Units; Male; Middle Aged; Netherlands; Oseltamivir; Pyrazines; Tertiary Care Centers	2018
Discharge Criteria for Patient With Lassa Fever Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 02-01, Volume: 66, Issue:4 Topics: Amides; Humans; Lassa Fever; Patient Discharge; Pyrazines; Ribavirin	2018
Reply to Nicastri et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 02-01, Volume: 66, Issue:4 Topics: Amides; Humans; Lassa Fever; Pyrazines; Ribavirin	2018
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. The Journal of infectious diseases, 2018, 03-05, Volume: 217, Issue:6 Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir	2018
QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:12 Topics: Adult; Amides; Antiviral Agents; Arrhythmias, Cardiac; Ebolavirus; Electrocardiography; Hemorrhagic Fever, Ebola; Humans; Italy; Levofloxacin; Male; Pyrazines; RNA-Dependent RNA Polymerase; Virus Replication	2017
Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral research, 2018, Volume: 151 Topics: Amides; Animals; Antiviral Agents; Cell Line; Cell Survival; Cytoplasm; Disease Models, Animal; Dose-Response Relationship, Drug; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Marburgvirus; Mice, Inbred C57BL; Pyrazines; Survival Analysis; Virus Replication	2018
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral research, 2018, Volume: 151 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Male; Marburg Virus Disease; Marburgvirus; Primates; Pyrazines; RNA, Viral; Survival Analysis; Viral Load	2018
Nubia's mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola. Reproductive health, 2017, Dec-14, Volume: 14, Issue:Suppl 3 Topics: Africa, Western; Amides; Antibodies, Monoclonal; Antiviral Agents; Ebola Vaccines; Female; Guinea; Health Services Accessibility; Hemorrhagic Fever, Ebola; Humans; Pregnancy; Pregnancy Complications, Infectious; Pyrazines; Randomized Controlled Trials as Topic	2017
Synthesis of a Novel Class of 1,3-oxathiolane Nucleoside Derivatives of T- 705 and Evaluation of Their Anti-influenza A Virus and Anti-HIV Activity. Medicinal chemistry (Shariqah (United Arab Emirates)), 2018, Volume: 14, Issue:6 Topics: Amides; Animals; Anti-HIV Agents; Dogs; HEK293 Cells; HIV; Humans; Influenza A Virus, H1N1 Subtype; Isomerism; Madin Darby Canine Kidney Cells; Nucleosides; Pyrazines; Ribavirin; Thiophenes	2018
Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral research, 2018, Volume: 151 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Female; Marburg Virus Disease; Marburgvirus; Mice, Inbred BALB C; Pyrazines; RNA, Viral; Survival Analysis; Vero Cells; Viral Load; Virus Replication	2018
Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses, 2018, 02-09, Volume: 10, Issue:2 Topics: Amides; Animals; Antiviral Agents; Apoptosis; Cell Line; Cell Proliferation; Chlorocebus aethiops; Humans; Pyrazines; Ribavirin; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection	2018
Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication. Vaccine, 2019, 08-02, Volume: 37, Issue:33 Topics: Amides; Animals; Antiviral Agents; Cell Line, Tumor; Drug Combinations; Interferon Type I; Mice; Pyrazines; Rabies virus; Real-Time Polymerase Chain Reaction; Ribavirin; Sorafenib; Virus Replication	2019
In vitro sensitivity of human parainfluenza 3 clinical isolates to ribavirin, favipiravir and zanamivir. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2018, Volume: 102 Topics: Amides; Antiviral Agents; Cell Line, Tumor; Cytopathogenic Effect, Viral; Humans; Parainfluenza Virus 3, Human; Pyrazines; Respirovirus Infections; Ribavirin; Virus Attachment; Virus Replication; Zanamivir	2018
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS medicine, 2018, Volume: 15, Issue:3 Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Ebolavirus; Female; Genome, Viral; Hemorrhagic Fever, Ebola; Humans; Macaca fascicularis; Mutagenesis; Pyrazines; RNA; Time Factors; Translational Research, Biomedical; Viral Load	2018
The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. Vaccine, 2019, 08-02, Volume: 37, Issue:33 Topics: Amides; Animals; Antibodies, Viral; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Immunity, Innate; Mice; Mice, Inbred C57BL; Pyrazines; Rabies; Rabies virus; Ribavirin; Serpins; Viral Proteins; Virus Replication	2019
Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:4 Topics: Amides; Antiviral Agents; Dengue; Dengue Virus; Humans; Mutagenesis; Mutation; Nucleosides; Pyrazines; Virus Replication	2018
Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients. The Journal of infectious diseases, 2018, 07-13, Volume: 218, Issue:4 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Female; Immunocompromised Host; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Male; Mice, Inbred NZB; Pyrazines; Ribavirin; Survival Analysis; Transplant Recipients; Treatment Outcome; Viral Load	2018
Extending the Antiviral Value of Favipiravir. The Journal of infectious diseases, 2018, 07-13, Volume: 218, Issue:4 Topics: Amides; Antiviral Agents; Humans; Lymphocytic choriomeningitis virus; Pyrazines; Transplant Recipients	2018
Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Scientific reports, 2018, 05-15, Volume: 8, Issue:1 Topics: Administration, Oral; Amides; Animals; Cricetinae; Disease Models, Animal; Female; Hendra Virus; Henipavirus Infections; Humans; Injections, Subcutaneous; Nipah Virus; Pyrazines; Transcription, Genetic; Treatment Outcome; Virus Replication	2018
Experimental drugs poised for use in Ebola outbreak. Nature, 2018, Volume: 557, Issue:7706 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal; Congo; Disease Outbreaks; Drugs, Investigational; Ebola Vaccines; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Internationality; Pyrazines; Ribonucleotides	2018
Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors. Journal of medicinal chemistry, 2018, Jul-26, Volume: 61, Issue:14 Topics: Amides; Animals; Antiviral Agents; Dogs; Madin Darby Canine Kidney Cells; Orthomyxoviridae; Prodrugs; Pyrazines; Ribonucleotides	2018
Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:9 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Epithelial Cells; Flavivirus; Fluorouracil; Mutagenesis; Mutagens; Mutation Rate; Nucleosides; Pyrazines; Ribavirin; Ribonucleosides; Serial Passage; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection	2018
Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral research, 2018, Volume: 157 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Mice; Pyrazines; Ribavirin; RNA, Viral; Survival Analysis; Treatment Outcome; Viral Load	2018
Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:9 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Humans; Models, Theoretical; Pyrazines; Vero Cells; Viral Load; Virus Replication; Zika Virus; Zika Virus Infection	2018
Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs. The Journal of infectious diseases, 2018, 11-22, Volume: 218, Issue:suppl_5 Topics: Amides; Animals; Antiviral Agents; Blood Cell Count; Chlorocebus aethiops; Female; Filoviridae Infections; Guinea Pigs; Pyrazines; RNA, Viral; Vero Cells; Virus Replication	2018
Resistance of high fitness hepatitis C virus to lethal mutagenesis. Virology, 2018, Volume: 523 Topics: Amides; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Genetic Fitness; Hepacivirus; Hepatocytes; Humans; Mutagenesis; Mutation; Pyrazines; Ribavirin; Serial Passage	2018
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nature communications, 2018, 10-01, Volume: 9, Issue:1 Topics: Amides; Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Host-Pathogen Interactions; Interferon-alpha; Macaca; Models, Theoretical; Pyrazines; Survival Analysis; Time Factors; Viral Load	2018
Rare haplotype load as marker for lethal mutagenesis. PloS one, 2018, Volume: 13, Issue:10 Topics: Amides; Antiviral Agents; Cell Line; Haplotypes; Hepacivirus; Humans; Mutation Rate; Nucleosides; Pyrazines; Quasispecies; Ribavirin; Serial Passage; Synthetic Lethal Mutations; Viral Nonstructural Proteins	2018
The mechanism of resistance to favipiravir in influenza. Proceedings of the National Academy of Sciences of the United States of America, 2018, 11-06, Volume: 115, Issue:45 Topics: Amides; Animals; Antiviral Agents; Arginine; Dogs; Drug Resistance, Viral; Gene Expression; Influenza A Virus, H1N1 Subtype; Lysine; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Mutation; Protein Subunits; Pyrazines; RNA-Dependent RNA Polymerase; Viral Proteins; Virus Replication	2018
Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration. PloS one, 2018, Volume: 13, Issue:10 Topics: Administration, Oral; Amides; Animals; Antibodies, Neutralizing; Chlorocebus aethiops; Disease Models, Animal; Dose-Response Relationship, Drug; Mice; Phlebotomus Fever; Phlebovirus; Pyrazines; Vero Cells	2018
Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. Journal of virology, 2019, 01-15, Volume: 93, Issue:2 Topics: Amides; Animals; Bias; DNA Primers; Dogs; HEK293 Cells; High-Throughput Nucleotide Sequencing; Humans; Influenza A virus; Madin Darby Canine Kidney Cells; Mutation; Pyrazines; Sequence Analysis, RNA; Whole Genome Sequencing	2019
Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice. Antiviral research, 2018, Volume: 160 Topics: Amides; Animal Structures; Animals; Antiviral Agents; Disease Models, Animal; Flavivirus; Flavivirus Infections; Mice; Microbial Sensitivity Tests; Pyrazines; Treatment Outcome; Viral Load; Virus Replication	2018
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses, 2018, 11-03, Volume: 10, Issue:11 Topics: Amides; Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Drug Resistance, Viral; Drug Therapy, Combination; Female; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines	2018
Mutagenesis in Norovirus in Response to Favipiravir Treatment. The New England journal of medicine, 2018, 11-29, Volume: 379, Issue:22 Topics: Amides; Antiviral Agents; Caliciviridae Infections; Chronic Disease; Common Variable Immunodeficiency; Diarrhea; Fatal Outcome; Humans; Male; Middle Aged; Mutagenesis; Norovirus; Pyrazines	2018
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. The Journal of antimicrobial chemotherapy, 2019, 05-01, Volume: 74, Issue:5 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Disease Models, Animal; Dogs; Epithelial Cells; Female; Immunocompromised Host; Influenza B virus; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Mice, SCID; Orthomyxoviridae Infections; Pyrazines; Viral Load; Virus Replication	2019
Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir. Viruses, 2019, 02-03, Volume: 11, Issue:2 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Ebolavirus; Female; Filoviridae; Filoviridae Infections; Gene Knockout Techniques; Hemorrhagic Fever, Ebola; Liver; Male; Marburg Virus Disease; Marburgvirus; Mice; Mice, Knockout; Proof of Concept Study; Pyrazines; Receptors, Interferon; RNA, Viral; Spleen; Virulence	2019
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study. The Journal of infectious diseases, 2019, 06-19, Volume: 220, Issue:2 Topics: Adolescent; Adult; Amides; Antiviral Agents; Child; Child, Preschool; Compassionate Use Trials; Ebolavirus; Female; Guinea; Hemorrhagic Fever, Ebola; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazines; Retrospective Studies; Viral Load; Young Adult	2019
Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral research, 2019, Volume: 167 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Dogs; HEK293 Cells; Humans; Madin Darby Canine Kidney Cells; Pyrazines; Ribonucleosides; RNA Viruses; Vero Cells	2019
Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:8 Topics: Amides; Animals; Base Sequence; Cell Line; Chlorocebus aethiops; Culicidae; Mutagenesis; Pyrazines; Rift Valley fever virus; RNA, Viral; Vero Cells	2019
Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS pathogens, 2019, Volume: 15, Issue:6 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Humans; Mice; Mice, Knockout; Orthomyxoviridae Infections; Pyrazines; Receptor, Interferon alpha-beta; Thogotovirus; Vero Cells; Viral Tropism	2019
T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques. Antiviral research, 2019, Volume: 170 Topics: Amides; Animals; Antiviral Agents; DNA, Viral; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Macaca; Male; Marburg Virus Disease; Marburgvirus; Mutagenesis; Pyrazines; Viremia	2019
Establishment of a Cell Culture Model of Persistent Flaviviral Infection: Usutu Virus Shows Sustained Replication during Passages and Resistance to Extinction by Antiviral Nucleosides. Viruses, 2019, 06-17, Volume: 11, Issue:6 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Flavivirus; Flavivirus Infections; Models, Biological; Pyrazines; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Sequence Deletion; Serial Passage; Treatment Outcome; Vero Cells; Viral Load; Viral Proteins; Virus Cultivation; Virus Replication	2019
Antiviral efficacy of favipiravir against canine distemper virus infection in vitro. BMC veterinary research, 2019, Sep-02, Volume: 15, Issue:1 Topics: Amides; Animals; Antiviral Agents; Cell Line; Cell Survival; Distemper Virus, Canine; Pyrazines	2019
Growth activation of influenza virus by trypsin and effect of T-705 (favipiravir) on trypsin-optimized growth condition. Acta virologica, 2019, Volume: 63, Issue:3 Topics: Amides; Antiviral Agents; Cell Line; Gene Expression Regulation, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Oseltamivir; Pyrazines; RNA, Viral; Trypsin	2019
Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral research, 2019, Volume: 172 Topics: Amides; Animals; Antiviral Agents; Cell Line; Central Nervous System; Diagnostic Imaging; Luminescent Measurements; Mice; Pyrazines; Rabies; Rabies virus; Viral Load; Virus Replication	2019
Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705). Infection, 2020, Volume: 48, Issue:2 Topics: Adult; Amides; Antiviral Agents; Bunyaviridae Infections; Humans; Male; Middle Aged; Phlebovirus; Pyrazines; Treatment Outcome	2020
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:11 Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabetes Mellitus, Type 1; Drug Repositioning; Enterovirus B, Human; Fluoxetine; Guanidine; Humans; Immunoglobulin G; Lovastatin; Oxadiazoles; Oxazoles; Oximes; Pyrazines; Ribavirin; Sulfonamides	2020
Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. The Journal of infectious diseases, 2020, 04-27, Volume: 221, Issue:10 Topics: Aged; Amides; Antiviral Agents; Critical Illness; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrazines; Retrospective Studies	2020
Antiviral activity of ribavirin and favipiravir against human astroviruses. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2020, Volume: 123 Topics: Amides; Antiviral Agents; Caco-2 Cells; Humans; Mamastrovirus; Pyrazines; Ribavirin; Virus Replication	2020
Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 10-23, Volume: 71, Issue:7 Topics: Amides; Antiviral Agents; Child; Humans; Influenza, Human; Pyrazines; Zanamivir	2020
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Antiviral research, 2020, Volume: 177 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Macaca fascicularis; Pyrazines; Ribavirin; Viral Load; Virus Replication	2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Humans; Indoles; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleotides; SARS-CoV-2; Virus Replication	2020
Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology, 2020, Volume: 545 Topics: Amides; Animals; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza B virus; Influenza, Human; Mice; Mice, Inbred C57BL; Oseltamivir; Pyrazines	2020
Advance of promising targets and agents against COVID-19 in China. Drug discovery today, 2020, Volume: 25, Issue:5 Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins	2020
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy. Heredity, 2020, Volume: 124, Issue:5 Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Models, Genetic; Mutation; Mutation Accumulation; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2	2020
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral research, 2020, Volume: 178 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Emetine; Epithelial Cells; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; SARS-CoV-2; Vero Cells; Virus Replication	2020
Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020. Emerging infectious diseases, 2020, Volume: 26, Issue:7 Topics: Amides; Animals; Belgium; Disease Models, Animal; Female; Humans; Junin virus; Pyrazines; Ribavirin	2020
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Current medicinal chemistry, 2020, Volume: 27, Issue:27 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2	2020
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2 Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2". Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2 Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Communications biology, 2020, 05-07, Volume: 3, Issue:1 Topics: Amides; Animals; Antibodies, Monoclonal; Antiviral Agents; Drug Therapy, Combination; Female; Hemagglutinins, Viral; Influenza A Virus, H1N1 Subtype; Mice; Mice, Nude; Orthomyxoviridae Infections; Pyrazines	2020
Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks. The journal of physical chemistry letters, 2020, Jun-04, Volume: 11, Issue:11 Topics: Adenine; Adenosine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus Infections; COVID-19; Humans; Molecular Docking Simulation; Nucleotidyltransferases; Pandemics; Pneumonia, Viral; Protein Structure, Tertiary; Pyrazines; Pyrrolidines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2020
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury. The New England journal of medicine, 2020, May-28, Volume: 382, Issue:22 Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Continuous Renal Replacement Therapy; Coronavirus Infections; COVID-19; Creatinine; Humans; Hypertension; Lung; Male; Obesity; Pandemics; Pneumonia, Viral; Pyrazines; Radiography, Thoracic; SARS-CoV-2	2020
Favipiravir, an antiviral for COVID-19? The Journal of antimicrobial chemotherapy, 2020, 07-01, Volume: 75, Issue:7 Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2	2020
Coronavirus 19 presenting with atypical Sweet's syndrome. Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:10 Topics: Amides; Antibodies, Monoclonal, Humanized; Biopsy, Needle; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; Erythema; Facial Dermatoses; Female; Fever; Humans; Immunohistochemistry; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Real-Time Polymerase Chain Reaction; Sweet Syndrome; Tomography, X-Ray Computed	2020
Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein. PLoS neglected tropical diseases, 2020, Volume: 14, Issue:6 Topics: Amides; Deubiquitinating Enzymes; DNA-Directed RNA Polymerases; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Humans; Mutation; Protein Structure, Tertiary; Pyrazines; Ribavirin; RNA, Viral; Virus Replication	2020
In vitro inhibition of mumps virus replication by favipiravir (T-705). Antiviral research, 2020, Volume: 180 Topics: A549 Cells; Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Humans; Mumps virus; Pyrazines; RNA, Viral; Vero Cells; Virus Replication	2020
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS neglected tropical diseases, 2020, Volume: 14, Issue:6 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Heart Conduction System; Hemorrhagic Fevers, Viral; Humans; Pyrazines	2020
A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient. Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:1 Topics: Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19 Drug Treatment; Humans; Kidney Transplantation; Male; Middle Aged; Pyrazines; SARS-CoV-2; Transplant Recipients	2021
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? European journal of cancer (Oxford, England : 1990), 2020, Volume: 136 Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2	2020
Coinfection with SARS-CoV-2 and influenza A virus. BMJ case reports, 2020, Jul-01, Volume: 13, Issue:7 Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Diagnosis, Differential; Glucocorticoids; Humans; Influenza A virus; Influenza, Human; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Radiography; Real-Time Polymerase Chain Reaction; SARS-CoV-2	2020
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Critical care (London, England), 2020, 07-03, Volume: 24, Issue:1 Topics: Aged; Amides; Benzamidines; Coronavirus Infections; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Female; Guanidines; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome	2020
Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral research, 2020, Volume: 181 Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Schedule; Female; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Macaca fascicularis; Male; Pyrazines; Viral Load; Viremia; Virus Shedding	2020
Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Critical care (London, England), 2020, 07-09, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Amides; Anti-Inflammatory Agents; Coronavirus Infections; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Prospective Studies; Pyrazines; Treatment Outcome	2020
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. SLAS discovery : advancing life sciences R & D, 2020, Volume: 25, Issue:10 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cyclopropanes; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Mice, Transgenic; Proline; Pyrazines; SARS-CoV-2; Small Molecule Libraries; Sulfonamides; Vaccines, Synthetic	2020
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking. Journal of nanoscience and nanotechnology, 2020, 12-01, Volume: 20, Issue:12 Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins	2020
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU Turkish journal of medical sciences, 2021, 04-30, Volume: 51, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Therapy, Combination; Early Medical Intervention; Early Warning Score; Female; Hospitalization; Humans; Hydroxychloroquine; Intensive Care Units; Length of Stay; Male; Middle Aged; Prospective Studies; Pyrazines; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Young Adult	2021
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Internal medicine (Tokyo, Japan), 2020, Sep-15, Volume: 59, Issue:18 Topics: Adult; Amides; Antiviral Agents; Arthritis, Gouty; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hyperuricemia; Lung; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Uric Acid	2020
Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ open, 2020, 07-31, Volume: 10, Issue:7 Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome	2020
Favipiravir. The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:8 Topics: Amides; Antiviral Agents; Pyrazines	2020
Reactive arthritis after COVID-19 infection. RMD open, 2020, Volume: 6, Issue:2 Topics: Adrenal Cortex Hormones; Amides; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthritis, Reactive; Arthrocentesis; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Injections, Intra-Articular; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prohibitins; Pyrazines; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2	2020
2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705. Archives of virology, 2020, Volume: 165, Issue:11 Topics: Amides; Animals; Antiviral Agents; Caliciviridae Infections; Cell Line; Deoxycytidine; Humans; Mice; Mycophenolic Acid; Norovirus; Pyrazines; RAW 264.7 Cells; Ribavirin; Virus Replication	2020
New anti-viral drugs for the treatment of COVID-19 instead of favipiravir. Journal of biomolecular structure & dynamics, 2021, Volume: 39, Issue:18 Topics: Amides; Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Pharmaceutical Preparations; Pyrazines; SARS-CoV-2	2021
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients. Critical care (London, England), 2020, 08-12, Volume: 24, Issue:1 Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2	2020
Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus. Antiviral research, 2020, Volume: 182 Topics: Amides; Animals; Antiviral Agents; Cell Line; Chikungunya Fever; Chikungunya virus; Female; Genotype; Humans; Mice; Mice, Inbred DBA; Phenotype; Phylogeny; Pyrazines	2020
Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020, Volume: 59, Issue:6 Topics: Aged; Amides; COVID-19; COVID-19 Drug Treatment; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Pneumonia; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed	2020
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors. Critical care (London, England), 2020, 08-18, Volume: 24, Issue:1 Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2	2020
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 100 Topics: Amides; Antiviral Agents; Humans; Male; Middle Aged; Pandemics; Pyrazines; SARS-CoV-2; Treatment Outcome	2020
Antiviral Effect of Favipiravir (T-705) against Measles and Subacute Sclerosing Panencephalitis Viruses. Japanese journal of infectious diseases, 2021, Mar-24, Volume: 74, Issue:2 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Humans; Interferon-alpha; Japan; Measles; Measles virus; Microbial Sensitivity Tests; Pyrazines; Ribavirin; SSPE Virus; Subacute Sclerosing Panencephalitis; Vero Cells	2021
Characteristics and Management of Children with COVID-19 in Turkey Balkan medical journal, 2020, 10-23, Volume: 37, Issue:6 Topics: Adolescent; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVID-19; Extracorporeal Membrane Oxygenation; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Male; Pandemics; Patient Acuity; Pneumonia, Viral; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey	2020
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates. Scientific reports, 2020, 08-31, Volume: 10, Issue:1 Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Discovery; Humans; Lopinavir; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2	2020
Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases. Journal of medical virology, 2021, Volume: 93, Issue:2 Topics: Adult; Amides; COVID-19; Critical Illness; Female; Humans; Male; Middle Aged; Pyrazines	2021
Comment on: Favipiravir, an antiviral for COVID-19? The Journal of antimicrobial chemotherapy, 2021, 01-01, Volume: 76, Issue:1 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pandemics; Pyrazines; SARS-CoV-2	2021
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respiratory investigation, 2020, Volume: 58, Issue:6 Topics: Amides; Antiviral Agents; COVID-19; Humans; Methylprednisolone; Pyrazines; SARS-CoV-2; Treatment Outcome	2020
Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020, Volume: 26, Issue:12 Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Decision Making; Extracorporeal Membrane Oxygenation; Hospitalization; Humans; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Viral Load	2020
Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN case reports, 2021, Volume: 10, Issue:1 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Kidney Failure, Chronic; Middle Aged; Pandemics; Positive-Pressure Respiration; Pyrazines; Renal Dialysis; SARS-CoV-2	2021
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nature communications, 2020, 09-17, Volume: 11, Issue:1 Topics: Amides; Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Models, Molecular; Mutagenesis; Pandemics; Pneumonia, Viral; Pyrazines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sequence Analysis; Vero Cells; Viral Nonstructural Proteins; Virus Replication	2020
The effects of favipiravir on hematological parameters of covıd-19 patients. Revista da Associacao Medica Brasileira (1992), 2020, Volume: 66Suppl 2, Issue:Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Amides; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; Female; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Pandemics; Platelet Count; Pneumonia, Viral; Pyrazines; Retrospective Studies; SARS-CoV-2	2020
Could ferritin level be an indicator of COVID-19 disease mortality? Journal of medical virology, 2021, Volume: 93, Issue:3 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Female; Ferritins; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prognosis; Pyrazines; SARS-CoV-2; Severity of Illness Index	2021
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). Antimicrobial agents and chemotherapy, 2020, 11-17, Volume: 64, Issue:12 Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; SARS-CoV-2; Severe Acute Respiratory Syndrome	2020
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Critical care (London, England), 2020, 09-25, Volume: 24, Issue:1 Topics: Administration, Oral; Aged; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; RNA, Viral; SARS-CoV-2; Virus Shedding	2020
Favipiravir-induced fever in coronavirus disease 2019: A report of two cases. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 101 Topics: Adult; Amides; Antiviral Agents; Body Temperature; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Fever; Humans; Male; Pyrazines; SARS-CoV-2; Treatment Outcome	2020
Favipiravir for COVID-19 in a Patient on Hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021, Volume: 77, Issue:1 Topics: Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Male; Pyrazines; Renal Dialysis	2021
Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey. Clinical pediatrics, 2021, Volume: 60, Issue:3 Topics: Adolescent; Amides; Antiviral Agents; Child; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Lung; Male; Pediatrics; Pyrazines; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Tertiary Care Centers; Treatment Outcome; Turkey	2021
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 10-27, Volume: 117, Issue:43 Topics: Amides; Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Hydroxychloroquine; Lung; Pyrazines; SARS-CoV-2; Treatment Outcome; Vero Cells; Viral Load	2020
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 2020, 10-08, Volume: 12, Issue:10 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cell Line; Dibenzothiepins; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Morpholines; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Pyridones; Ribavirin; Triazines; Viral Proteins; Virus Replication; Zanamivir	2020
Unexpected complete recovery of a patient with severe tick-borne encephalitis treated with favipiravir. Antiviral research, 2020, Volume: 184 Topics: Adult; Amides; Diagnosis, Differential; Encephalitis Viruses, Tick-Borne; Encephalitis, Tick-Borne; Humans; Male; Pyrazines; Vaccination; West Nile Fever; Young Adult	2020
Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 08-02, Volume: 73, Issue:3 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2	2021
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral research, 2020, Volume: 184 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Flow Cytometry; Heart Diseases; Humans; Hydroxychloroquine; Microscopy, Fluorescence; Myocytes, Cardiac; Pluripotent Stem Cells; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Vero Cells; Viral Plaque Assay	2020
DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021, Feb-15, Volume: 247 Topics: Amides; COVID-19; COVID-19 Drug Treatment; Fullerenes; Humans; Molecular Structure; Pandemics; Pyrazines; SARS-CoV-2; Spectrophotometry, Infrared	2021
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:2 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Female; Humans; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Mortality; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome; Turkey	2021
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. European journal of pharmacology, 2021, Jan-05, Volume: 890 Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Binding Sites; COVID-19 Drug Treatment; Drug Repositioning; Esters; Gabexate; Guanidines; Molecular Docking Simulation; Phytochemicals; Protein Binding; Pyrazines; Raltegravir Potassium; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stavudine; Tenofovir	2021
Scientists criticize use of unproven COVID drugs in India. Nature, 2020, Volume: 587, Issue:7833 Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Drugs, Investigational; Humans; Hydroxychloroquine; India; Patient Safety; Placebos; Pyrazines; Reproducibility of Results; SARS-CoV-2; Time Factors; United States; Virus Shedding	2020
Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M BMC research notes, 2020, Nov-11, Volume: 13, Issue:1 Topics: Amides; Antiviral Agents; Benzaldehydes; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus 3C Proteases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Hydroxychloroquine; Laurates; Microbial Sensitivity Tests; Models, Molecular; Monoglycerides; Pyrazines; SARS-CoV-2; Structure-Activity Relationship; Tetrodotoxin; Viral Nonstructural Proteins	2020
A Favipiravir-induced Fever in a Patient with COVID-19. Internal medicine (Tokyo, Japan), 2020, Volume: 59, Issue:22 Topics: Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Fever; Humans; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2	2020
Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey Turkish journal of medical sciences, 2021, 06-28, Volume: 51, Issue:3 Topics: Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Follow-Up Studies; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Pyrazines; Retrospective Studies; SARS-CoV-2; Time Factors; Treatment Outcome; Turkey	2021
Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:8 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; Peptide Hydrolases; Protease Inhibitors; Pyrazines; Quantitative Structure-Activity Relationship; RNA; RNA-Dependent RNA Polymerase; SARS-CoV-2	2022
A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:2 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Nasopharynx; Nucleic Acid Amplification Techniques; Pneumonia, Viral; Pyrazines; Respiration, Artificial; RNA, Viral; SARS-CoV-2; Treatment Outcome; Viremia	2021
Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management. Antimicrobial agents and chemotherapy, 2021, 02-17, Volume: 65, Issue:3 Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2	2021
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19. Antimicrobial agents and chemotherapy, 2021, 02-17, Volume: 65, Issue:3 Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2	2021
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. The Journal of infection, 2021, Volume: 82, Issue:5 Topics: Amides; COVID-19; Humans; Japan; Pyrazines; SARS-CoV-2; Severity of Illness Index; Treatment Outcome	2021
Gender differences in treatment of Coronavirus Disease-2019. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Dec-03, Volume: 90, Issue:4 Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Complications; Female; Humans; Hypertension; Immunity; Immunization, Passive; Immunoglobulins; Lopinavir; Male; Middle Aged; Mortality; Pandemics; Pyrazines; Ritonavir; SARS-CoV-2; Sex Characteristics	2020
Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021, Mar-15, Volume: 249 Topics: Amides; Antiviral Agents; Blood Chemical Analysis; COVID-19; COVID-19 Drug Treatment; Humans; Limit of Detection; Pyrazines; SARS-CoV-2; Sensitivity and Specificity; Spectrometry, Fluorescence	2021
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. Endocrine journal, 2021, Apr-28, Volume: 68, Issue:4 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination	2021
Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity. BMJ case reports, 2020, Dec-18, Volume: 13, Issue:12 Topics: Amides; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diagnosis, Differential; Glucocorticoids; Humans; Male; Middle Aged; Prednisolone; Pyrazines; Radionuclide Imaging; SARS-CoV-2; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Subacute; Treatment Outcome; Ultrasonography, Doppler, Color	2020
Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:1 Topics: Adrenal Cortex Hormones; Aged; Amides; Antiviral Agents; COVID-19; Extracorporeal Membrane Oxygenation; Humans; Male; Methylprednisolone; Middle Aged; Pyrazines; Respiration, Artificial; Respiratory Insufficiency; SARS-CoV-2	2021
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:2 Topics: Aged; Amides; Antiviral Agents; Chemical and Drug Induced Liver Injury; Cholestasis; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Humans; Lopinavir; Male; Pyrazines; Ritonavir; SARS-CoV-2	2021
Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans. Dermatologic therapy, 2021, Volume: 34, Issue:1 Topics: Amides; COVID-19; Fluorescence; Humans; Nails; Pandemics; Pyrazines; SARS-CoV-2; Ultraviolet Rays	2021
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS computational biology, 2021, Volume: 17, Issue:1 Topics: Amides; Animals; Antiviral Agents; Female; Host-Pathogen Interactions; Lassa Fever; Lassa virus; Macaca fascicularis; Models, Biological; Pyrazines; Ribavirin; Viral Load	2021
Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. EBioMedicine, 2021, Volume: 63 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Influenza, Human; Orthomyxoviridae; Pyrazines; SARS-CoV-2	2021
[Clinical progression of the first wave of novel coronavirus infection in Ostrava]. Klinicka mikrobiologie a infekcni lekarstvi, 2020, Volume: 26, Issue:3 Topics: Adenosine Monophosphate; Aged; Alanine; Amides; COVID-19; Czech Republic; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Pyrazines; Respiration, Artificial	2020
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. Trials, 2021, Jan-15, Volume: 22, Issue:1 Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Hydroxychloroquine; Lopinavir; PubMed; Pyrazines; Registries; Research Design; Research Report; Ritonavir; SARS-CoV-2	2021
Synthesis of novel pyrimidine thioglycosides as structural analogs of favipiravir (avigan) and their antibird flu virus activity. Nucleosides, nucleotides & nucleic acids, 2021, Volume: 40, Issue:3 Topics: Amides; Antiviral Agents; Chemistry Techniques, Synthetic; Influenza A Virus, H5N1 Subtype; Pyrazines; Pyrimidines; Thioglycosides	2021
Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection. Photodermatology, photoimmunology & photomedicine, 2021, Volume: 37, Issue:4 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Luminescence; Nails; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Turkey; Ultraviolet Rays	2021
A finding associated with favipiravir-associated photosensitivity: Yellow-green fluorescence in the lunulae, scalp, and face. Dermatologic therapy, 2021, Volume: 34, Issue:2 Topics: Amides; Antiviral Agents; Fluorescence; Humans; Pyrazines; Scalp	2021
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-16, Volume: 118, Issue:7 Topics: Amides; Coronavirus RNA-Dependent RNA Polymerase; Cryoelectron Microscopy; Enzyme Inhibitors; Pyrazines; Ribonucleotides; SARS-CoV-2; Single Molecule Imaging	2021
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum Journal of pharmaceutical and biomedical analysis, 2021, Mar-20, Volume: 196 Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines	2021
Early clinical experience with imatinib in COVID-19: Searching for a dual effect. The Journal of infection, 2021, Volume: 82, Issue:5 Topics: Amides; COVID-19; Humans; Imatinib Mesylate; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient. Internal medicine (Tokyo, Japan), 2021, Apr-01, Volume: 60, Issue:7 Topics: Amides; Antiviral Agents; COVID-19; Fever; Humans; Male; Middle Aged; Pharmaceutical Preparations; Pyrazines; SARS-CoV-2	2021
Myositis due to COVID-19. Postgraduate medical journal, 2021, Volume: 97, Issue:1148 Topics: Adult; Amides; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Nucleic Acid Testing; Creatine Kinase; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Humans; Hydroxychloroquine; Lung; Lymphopenia; Magnetic Resonance Imaging; Male; Methylprednisolone; Muscle, Skeletal; Myositis; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed	2021
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 105 Topics: Amides; COVID-19; Humans; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2021
Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 105 Topics: Amides; COVID-19; Humans; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2021
A novel, rapid and simple UPLC-MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study. Biomedical chromatography : BMC, 2021, Volume: 35, Issue:7 Topics: Adult; Amides; Chromatography, High Pressure Liquid; Female; Humans; Limit of Detection; Male; Middle Aged; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult	2021
Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2021, Sep-10, Volume: 37, Issue:9 Topics: Amides; Blood Chemical Analysis; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Hospitals; Humans; Pyrazines; Time Factors	2021
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Liver Diseases; Male; Middle Aged; Phlebovirus; Pyrazines; RNA, Viral; Severe Fever with Thrombocytopenia Syndrome; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viral Load	2021
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. International immunopharmacology, 2021, Volume: 93 Topics: Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2	2021
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. Journal of infection and public health, 2021, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Intensive Care Units; Male; Middle Aged; Pyrazines; Retrospective Studies; Treatment Outcome; Young Adult	2021
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment Turkish journal of medical sciences, 2021, 08-30, Volume: 51, Issue:4 Topics: Aged; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome	2021
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nature communications, 2021, 03-19, Volume: 12, Issue:1 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Female; Genome, Viral; Lung; Mesocricetus; Pyrazines; SARS-CoV-2; Vero Cells; Viral Load	2021
Plain Magnetic resonance in chemistry : MRC, 2021, Volume: 59, Issue:7 Topics: Amides; Antiviral Agents; Drug Contamination; Niacinamide; Proton Magnetic Resonance Spectroscopy; Pyrazinamide; Pyrazines; Quality Control; World Health Organization	2021
Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir. International journal of clinical practice, 2021, Volume: 75, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19; Cross-Sectional Studies; Drug Combinations; Humans; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey	2021
A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 106 Topics: Amides; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Lymphocyte Activation; Middle Aged; Pyrazines; Viral Load	2021
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. Molecular diversity, 2022, Volume: 26, Issue:1 Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Repositioning; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines; Pyrrolidines; Ribavirin; RNA, Viral; SARS-CoV-2	2022
Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:3 Topics: Amides; Animals; Antiviral Agents; Cytokine Release Syndrome; Cytokines; Disease Models, Animal; Ebolavirus; Hemorrhagic Fever, Ebola; Macaca fascicularis; Pyrazines; T-Lymphocytes; Viral Load; Viremia; Virus Replication	2021
The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice. Viruses, 2021, 03-24, Volume: 13, Issue:4 Topics: Amides; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cricetinae; HEK293 Cells; Humans; Kidney; Male; Mice; Mice, Inbred BALB C; Pyrazines; Reverse Genetics; Rift Valley Fever; Rift Valley fever virus; Vero Cells; Viral Nonstructural Proteins; Virulence; Virulence Factors	2021
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Current problems in cancer, 2021, Volume: 45, Issue:6 Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine	2021
Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:7 Topics: Amides; China; COVID-19; Humans; Pyrazines; Real-Time Polymerase Chain Reaction; Recurrence; Reverse Transcription; SARS-CoV-2	2021
First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode. Analytica chimica acta, 2021, May-15, Volume: 1159 Topics: Amides; Antiviral Agents; Boron; Diamond; Electrodes; Humans; Pyrazines; SARS-CoV-2; Surface-Active Agents	2021
Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:3 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Double-Blind Method; Drug Approval; Humans; Japan; Pyrazines	2022
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Current medical research and opinion, 2021, Volume: 37, Issue:7 Topics: Amides; Antiviral Agents; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Saudi Arabia; Sensitivity and Specificity	2021
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult	2021
Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:7 Topics: Amides; Antiviral Agents; COVID-19; Humans; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2021
Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face. Journal of cosmetic dermatology, 2022, Volume: 21, Issue:3 Topics: Amides; Antiviral Agents; COVID-19; Female; Fluorescence; Humans; Nails; Pyrazines; SARS-CoV-2	2022
Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021, Volume: 60, Issue:4 Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Serotherapy; Critical Care; Female; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Hospital Mortality; Humans; Immunization, Passive; Leukocyte Count; Male; Middle Aged; Pandemics; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Time Factors; Turkey	2021
Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19. Journal of cosmetic dermatology, 2021, Volume: 20, Issue:8 Topics: Amides; COVID-19; Fluorescence; Humans; Nails; Pyrazines; SARS-CoV-2	2021
Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:19 Topics: Amides; COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; Pyrazines; SARS-CoV-2	2022
A case report of super responder of critical COVID-19 pneumonia. The journal of medical investigation : JMI, 2021, Volume: 68, Issue:1.2 Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Glucocorticoids; Humans; Lung; Male; Methylprednisolone; Pneumonia, Viral; Pyrazines; Receptors, Interleukin-6; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome	2021
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study. Virology journal, 2021, 05-25, Volume: 18, Issue:1 Topics: Aged; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2021
Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Jun-30, Volume: 1176 Topics: Amides; Antiviral Agents; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Drug Stability; Humans; Limit of Detection; Pyrazines; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2021
Management of COVID-19 pneumonia in a child with NEMO deficiency. Immunologic research, 2021, Volume: 69, Issue:4 Topics: Amides; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Serotherapy; Ectodermal Dysplasia; Genetic Diseases, X-Linked; Humans; Hydroxychloroquine; I-kappa B Kinase; Immunization, Passive; Male; Primary Immunodeficiency Diseases; Pyrazines; SARS-CoV-2	2021
Favipiravir-resistant influenza A virus shows potential for transmission. PLoS pathogens, 2021, Volume: 17, Issue:6 Topics: Amides; Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Pyrazines	2021
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. The Journal of antimicrobial chemotherapy, 2021, 07-15, Volume: 76, Issue:8 Topics: Amides; Animals; Antiviral Agents; COVID-19; Dogs; Humans; Polyphosphates; Pyrazines; SARS-CoV-2	2021
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. PloS one, 2021, Volume: 16, Issue:6 Topics: Adult; Aged; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Interferon beta-1b; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2	2021
Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case. Journal of cosmetic dermatology, 2021, Volume: 20, Issue:8 Topics: Acute Generalized Exanthematous Pustulosis; Amides; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pyrazines; SARS-CoV-2	2021
Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment. Journal of cosmetic dermatology, 2021, Volume: 20, Issue:8 Topics: Amides; COVID-19; Diabetic Foot; Humans; Pyrazines; SARS-CoV-2	2021
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19 Turkish journal of medical sciences, 2021, 12-13, Volume: 51, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Male; Middle Aged; Outpatients; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey; Young Adult	2021
Electron Density Analysis of SARS-CoV-2 RNA-Dependent RNA Polymerase Complexes. Molecules (Basel, Switzerland), 2021, Jun-28, Volume: 26, Issue:13 Topics: Algorithms; Amides; Antiviral Agents; Coronavirus RNA-Dependent RNA Polymerase; Electrons; Ligands; Molecular Structure; Protein Binding; Pyrazines; Ribonucleosides; SARS-CoV-2	2021
Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:7 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; Encephalitis Virus, California; Encephalitis, California; Female; Humans; Mice; Mice, Inbred C57BL; Pyrazines; Vero Cells	2021
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International immunopharmacology, 2022, Volume: 102 Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2	2022
Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19. The Journal of the Association of Physicians of India, 2021, Volume: 69, Issue:1 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2	2021
The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription. Biophysical chemistry, 2021, Volume: 277 Topics: Amides; Humans; Influenza, Human; Pyrazines; Viral Transcription	2021
Generation of a Bactrian camel hepatitis E virus by a reverse genetics system. The Journal of general virology, 2021, Volume: 102, Issue:7 Topics: Amides; Animals; Antiviral Agents; Capsid Proteins; Cell Line; Female; Genome, Viral; Hepatitis E; Hepatitis E virus; Humans; Macaca fascicularis; Male; Mice; Mice, Nude; Pyrazines; Rats; Reverse Genetics; Ribavirin; RNA, Viral; Transfection; Virus Replication	2021
Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation. Molecular pharmaceutics, 2021, 08-02, Volume: 18, Issue:8 Topics: Administration, Oral; Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Female; Ionic Liquids; Mice; Mice, Inbred BALB C; Pyrazines; Solubility; Tissue Distribution	2021
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Topics: Amides; Antiviral Agents; Bone Neoplasms; Chemical and Drug Induced Liver Injury; COVID-19; Humans; Methotrexate; Osteosarcoma; Pharmaceutical Preparations; Pyrazines; RNA, Viral; SARS-CoV-2	2022
Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report. Virology journal, 2021, 07-13, Volume: 18, Issue:1 Topics: Adult; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Eye; Fluorescence; Humans; Male; Pyrazines; SARS-CoV-2	2021
Population pharmacokinetics of favipiravir in patients with COVID-19. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Theoretical; Pyrazines; Retrospective Studies; Tandem Mass Spectrometry; Treatment Outcome	2021
Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:3 Topics: Amides; Anticoagulants; COVID-19 Drug Treatment; Drug Interactions; Humans; International Normalized Ratio; Pyrazines; Warfarin	2022
New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2. ChemMedChem, 2021, 11-19, Volume: 16, Issue:22 Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Coronavirus RNA-Dependent RNA Polymerase; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pyrazines; Quantitative Structure-Activity Relationship; SARS-CoV-2; Vero Cells	2021
STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV). Viruses, 2021, 07-17, Volume: 13, Issue:7 Topics: Amides; Animals; Antibodies, Viral; Antiviral Agents; Disease Models, Animal; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Male; Mice; Mice, Knockout; Pyrazines; STAT1 Transcription Factor; Viral Proteins	2021
Electron attachment to isolated and microhydrated favipiravir. Physical chemistry chemical physics : PCCP, 2021, Oct-06, Volume: 23, Issue:38 Topics: Amides; Electrons; Pyrazines; Water	2021
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19. Cardiovascular & hematological disorders drug targets, 2021, Volume: 21, Issue:2 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Heart Diseases; Humans; Pyrazines; SARS-CoV-2	2021
Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. FEBS letters, 2021, Volume: 595, Issue:18 Topics: Amides; Antiviral Agents; Drug Resistance, Viral; Mutation; Point Mutation; Pyrazines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2	2021
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients Turkish journal of medical sciences, 2021, 12-13, Volume: 51, Issue:6 Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Amides; Antiviral Agents; Clinical Protocols; COVID-19; COVID-19 Nucleic Acid Testing; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Middle Aged; Oseltamivir; Pandemics; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Young Adult	2021
Alectinib, COVID-19 and favipiravir. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:7 Topics: Amides; Carbazoles; COVID-19; Humans; Piperidines; Pyrazines; SARS-CoV-2	2021
Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. Journal of infection and public health, 2021, Volume: 14, Issue:9 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Retrospective Studies; SARS-CoV-2; Standard of Care; Treatment Outcome	2021
Favipiravir Induced Nephrotoxicity in two Patients of COVID-19. The Journal of the Association of Physicians of India, 2021, Volume: 69, Issue:6 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary. GeroScience, 2021, Volume: 43, Issue:5 Topics: Amides; Cohort Studies; COVID-19 Drug Treatment; Disease Progression; Humans; Hungary; Prospective Studies; Pyrazines; SARS-CoV-2; Treatment Outcome	2021
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave. Journal of medical virology, 2022, Volume: 94, Issue:1 Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Male; Methylprednisolone; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Turkey	2022
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022, 02-23, Volume: 39, Issue:1 Topics: Adult; Amides; Azithromycin; Child; COVID-19; Hematologic Neoplasms; Humans; Hydroxychloroquine; Pyrazines; SARS-CoV-2; Turkey	2022
Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights. Drug research, 2022, Volume: 72, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2	2022
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, Volume: 72 Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load	2021
Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19. Clinical and experimental dermatology, 2022, Volume: 47, Issue:3 Topics: Adult; Amides; Antiviral Agents; COVID-19 Drug Treatment; Drug Eruptions; Female; Humans; Middle Aged; Pyrazines; Urticaria; Young Adult	2022
Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective. Scientific reports, 2021, 10-07, Volume: 11, Issue:1 Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Design; Drug Discovery; Humans; Metabolic Networks and Pathways; Molecular Docking Simulation; Nitro Compounds; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Thiazoles	2021
Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:1 Topics: Amides; Antiviral Agents; COVID-19; Humans; Minocycline; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2022
Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury. Journal of infection in developing countries, 2021, 09-30, Volume: 15, Issue:9 Topics: Acute Kidney Injury; Adult; Amides; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Male; Mycophenolic Acid; Pyrazines; Ritonavir; Steroids; Tacrolimus; Thailand; Transplant Recipients	2021
The relationship between Covid-19 and mucociliary clearance. Acta oto-laryngologica, 2021, Volume: 141, Issue:11 Topics: Adrenal Cortex Hormones; Adult; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Middle Aged; Mucociliary Clearance; Nasal Mucosa; Pyrazines; Smoking	2021
Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:1 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Ferritins; Humans; Pyrazines; Retrospective Studies; SARS-CoV-2; Uric Acid	2022
African scientists race to test COVID drugs - but face major hurdles. Nature, 2021, Volume: 599, Issue:7883 Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization	2021
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? EBioMedicine, 2021, Volume: 74 Topics: Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Pyrazines; SARS-CoV-2	2021
Hematological Malignancy Patients, COVID-19, and Favipiravir Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, 12-07, Volume: 38, Issue:4 Topics: Amides; COVID-19; Hematologic Neoplasms; Humans; Pyrazines; SARS-CoV-2	2021
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. Rheumatology international, 2022, Volume: 42, Issue:1 Topics: Adolescent; Adult; Amides; Antiviral Agents; Behcet Syndrome; Comorbidity; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Incidence; Male; Middle Aged; Prospective Studies; Pyrazines; Treatment Outcome; Young Adult	2022
An AGEP case due to COVİD-19 or favipiravir or enoxaparin. Journal of cosmetic dermatology, 2022, Volume: 21, Issue:1 Topics: Amides; COVID-19; Enoxaparin; Humans; Pyrazines; SARS-CoV-2	2022
An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19. Indian journal of ophthalmology, 2021, Volume: 69, Issue:12 Topics: Amides; Antiviral Agents; Cornea; COVID-19; Humans; Pyrazines; SARS-CoV-2	2021
Favipiravir Inhibits Mayaro Virus Infection in Mice. Viruses, 2021, 11-03, Volume: 13, Issue:11 Topics: Alanine Transaminase; Alphavirus; Alphavirus Infections; Amides; Animals; Antiviral Agents; Aspartate Aminotransferases; Cell Line; Chlorocebus aethiops; Disease Models, Animal; Female; Liver; Mice; Mice, Inbred C57BL; Pyrazines; Vero Cells; Virus Replication	2021
Voltammetric sensor based on bimetallic nanocomposite for determination of favipiravir as an antiviral drug. Mikrochimica acta, 2021, 11-27, Volume: 188, Issue:12 Topics: Amides; Antiviral Agents; Colloids; COVID-19 Drug Treatment; Electrochemistry; Electrodes; Gold; Humans; Limit of Detection; Linear Models; Metal Nanoparticles; Nanocomposites; Nanomedicine; Nanotechnology; Nanotubes; Polymers; Pyrazines	2021
Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. Scientific reports, 2021, 12-06, Volume: 11, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Binding Sites; Cell Culture Techniques; Cell Line; Coronavirus NL63, Human; Haplorhini; Humans; Molecular Docking Simulation; Pyrazines; RNA-Dependent RNA Polymerase; Virus Replication	2021
Favipiravir exposure and pregnancy outcome of COVID-19 patients. European journal of obstetrics, gynecology, and reproductive biology, 2022, Volume: 268 Topics: Amides; COVID-19; Female; Humans; Pregnancy; Pregnancy Outcome; Pyrazines; SARS-CoV-2	2022
Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 115 Topics: Amides; COVID-19; Humans; Hyperuricemia; Pyrazines; SARS-CoV-2; Uric Acid	2022
Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysi Current medical research and opinion, 2022, Volume: 38, Issue:3 Topics: Amides; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Retrospective Studies; SARS-CoV-2	2022
Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies. Viruses, 2021, 12-14, Volume: 13, Issue:12 Topics: Adenosine Triphosphate; Amides; Animals; Antimetabolites; Antiviral Agents; Cell Line; Drug Synergism; Guanosine Triphosphate; Humans; Methylthioinosine; Mutation; Phosphoribosyl Pyrophosphate; Pyrazines; RNA Viruses; RNA, Viral; Virus Replication	2021
Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2022, Jan-15, Volume: 1189 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Liquid Phase Microextraction; Menthol; Pyrazines; SARS-CoV-2	2022
Visual classification of three computed tomography lung patterns to predict prognosis of COVID-19: a retrospective study. BMC pulmonary medicine, 2022, Jan-03, Volume: 22, Issue:1 Topics: Adult; Aged; Amides; Antiviral Agents; Body Temperature; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Female; Fibrin Fibrinogen Degradation Products; Humans; L-Lactate Dehydrogenase; Lung; Lymphocyte Count; Male; Middle Aged; Mucin-1; Neutrophils; Predictive Value of Tests; Prognosis; Pyrazines; Radiographic Image Interpretation, Computer-Assisted; Retrospective Studies; SARS-CoV-2; Steroids; Tomography, X-Ray Computed	2022
Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2022, Volume: 20, Issue:2 Topics: Amides; COVID-19; Female; Humans; Kidney Transplantation; Male; Middle Aged; Pyrazines; Retrospective Studies; SARS-CoV-2; Transplant Recipients; Treatment Outcome	2022
Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals. The Journal of the Association of Physicians of India, 2022, Volume: 69, Issue:12 Topics: Amides; COVID-19; Cross-Sectional Studies; Delivery of Health Care; Humans; Pyrazines; SARS-CoV-2	2022
Angioedema after favipiravir treatment: Two cases. Journal of cosmetic dermatology, 2022, Volume: 21, Issue:9 Topics: Aged; Alanine Transaminase; Amides; Angioedema; Aspartate Aminotransferases; COVID-19 Drug Treatment; Humans; Pyrazines; Steroids	2022
Sinus bradycardia as a potential side effect of favipiravir treatment Orvosi hetilap, 2022, 02-13, Volume: 163, Issue:7 Topics: Amides; Bradycardia; Coronavirus; Coronavirus Infections; Humans; Pandemics; Pyrazines	2022
Favipiravir in the Battle with Respiratory Viruses. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:17 Topics: Amides; Animals; Antiviral Agents; COVID-19; Humans; Pyrazines; RNA Viruses; Virus Diseases; Viruses	2022
Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir. Diagnostic microbiology and infectious disease, 2022, Volume: 102, Issue:4 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; Retrospective Studies; Risk Factors; SARS-CoV-2; Treatment Outcome; Uric Acid	2022
Detailed Analyses of Molecular Interactions between Favipiravir and RNA Viruses In Silico. Viruses, 2022, 02-07, Volume: 14, Issue:2 Topics: Amides; Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Magnesium; Molecular Docking Simulation; Nucleotides; Protein Conformation; Pyrazines; RNA Viruses; RNA-Dependent RNA Polymerase; RNA, Viral; Sequence Alignment	2022
Ab Initio Insight into the Interaction of Metal-Decorated Fluorinated Carbon Fullerenes with Anti-COVID Drugs. International journal of molecular sciences, 2022, Feb-21, Volume: 23, Issue:4 Topics: Amides; Antiviral Agents; Chloroquine; COVID-19; Density Functional Theory; Drug Carriers; Drug Delivery Systems; Fullerenes; Halogenation; Metals; Models, Molecular; Nickel; Pyrazines	2022
Core-shell nanocomposite of flower-like molybdenum disulfide nanospheres and molecularly imprinted polymers for electrochemical detection of anti COVID-19 drug favipiravir in biological samples. Mikrochimica acta, 2022, 03-01, Volume: 189, Issue:3 Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disulfides; Electrochemical Techniques; Humans; Limit of Detection; Molecularly Imprinted Polymers; Molybdenum; Nanocomposites; Nanospheres; Oxidation-Reduction; Pyrazines; Reproducibility of Results; SARS-CoV-2	2022
Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. International journal of molecular sciences, 2022, Feb-27, Volume: 23, Issue:5 Topics: Amides; Hepatitis A; Hepatitis A Antibodies; Hepatitis A virus; Hepatocytes; Humans; Nucleotides; Pyrazines; Ribavirin; RNA, Viral; Virus Replication	2022
A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid-liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. Biomedical chromatography : BMC, 2022, Volume: 36, Issue:6 Topics: Amides; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Furans; Gadolinium; Humans; Ionic Liquids; Liquid Phase Microextraction; Magnetic Phenomena; Pyrazines	2022
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. Journal of infection and public health, 2022, Volume: 15, Issue:4 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; COVID-19 Vaccines; Critical Illness; Humans; Intensive Care Units; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Saudi Arabia	2022
Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID-19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids. Luminescence : the journal of biological and chemical luminescence, 2022, Volume: 37, Issue:6 Topics: Amides; COVID-19 Drug Treatment; Drug Compounding; Humans; Hydroxychloroquine; Pharmaceutical Preparations; Pyrazines; SARS-CoV-2; Spectrometry, Fluorescence; United States; United States Food and Drug Administration	2022
COVID-19 and favipiravir induce cutaneous adverse reactions: a difficulty in clinical dermatology practice. Clinical and experimental dermatology, 2022, Volume: 47, Issue:7 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Dermatology; Exanthema; Humans; Pyrazines	2022
Fully validated UPLC-MS/MS method for quantifying Favipiravir in human plasma boosted lean six sigma: An application for a bioequivalence study. Biomedical chromatography : BMC, 2022, Volume: 36, Issue:9 Topics: Amides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry; Therapeutic Equivalency; Total Quality Management	2022
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment? Journal of infection in developing countries, 2022, 03-31, Volume: 16, Issue:3 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2022
Anti-Influenza Virus Study of Composite Material with MIL-101(Fe)-Adsorbed Favipiravir. Molecules (Basel, Switzerland), 2022, Mar-31, Volume: 27, Issue:7 Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Metal-Organic Frameworks; Pyrazines	2022
Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen. Molecules (Basel, Switzerland), 2022, Apr-04, Volume: 27, Issue:7 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Micelles; Pandemics; Pyrazines; Reproducibility of Results; SARS-CoV-2; Spectrophotometry, Ultraviolet	2022
Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach. Drug and chemical toxicology, 2023, Volume: 46, Issue:3 Topics: Amides; Animals; Antiviral Agents; Aquaporin 2; Kidney; Liver; Pyrazines; Rats	2023
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir. Viruses, 2022, 03-24, Volume: 14, Issue:4 Topics: Amides; Antibodies, Neutralizing; Antibodies, Viral; COVID-19 Drug Treatment; Humans; Immunoglobulin G; Neutralization Tests; Pyrazines; SARS-CoV-2; Spike Glycoprotein, Coronavirus	2022
Theoretical insights of the drug-drug interaction between favipiravir and ibuprofen: a DFT, QTAIM and drug-likeness investigation. Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:10 Topics: Amides; Drug Interactions; Ibuprofen; Pyrazines	2023
Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19? GeroScience, 2022, Volume: 44, Issue:3 Topics: Aged; Amides; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome	2022
Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:10 Topics: Adult; Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pyrazines; Treatment Outcome	2022
Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations. Journal of separation science, 2022, Volume: 45, Issue:14 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; COVID-19 Drug Treatment; Cytidine; Drug Compounding; Humans; Hydroxylamines; Pyrazines; Reproducibility of Results; Ritonavir; SARS-CoV-2	2022
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19. Biotechnology letters, 2022, Volume: 44, Issue:7 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyglucose; Hexokinase; Humans; Hydroxylamines; Molecular Docking Simulation; Pyrazines; SARS-CoV-2	2022
Is Favipiravir a Potential Therapeutic Agent in the Treatment of Intervertebral Disc Degeneration by Suppressing Autophagy and Apoptosis? Turkish neurosurgery, 2022, Volume: 32, Issue:4 Topics: Amides; Apoptosis; Autophagy; Cells, Cultured; Humans; Interleukin-1beta; Intervertebral Disc; Intervertebral Disc Degeneration; NF-kappa B; Pyrazines	2022
Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel. International journal of clinical practice, 2022, Volume: 2022 Topics: Adrenal Cortex Hormones; Adult; Aged; Ageusia; Amides; Antiviral Agents; COVID-19 Drug Treatment; Dyspnea; Humans; Pyrazines; Retrospective Studies; SARS-CoV-2	2022
Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers. Biochemistry, 2022, 07-05, Volume: 61, Issue:13 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Lipid Bilayers; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2022
Analytical Performance and Greenness Evaluation of Five Multi-Level Design Models Utilized for Impurity Profiling of Favipiravir, a Promising COVID-19 Antiviral Drug. Molecules (Basel, Switzerland), 2022, Jun-07, Volume: 27, Issue:12 Topics: Algorithms; Amides; Antiviral Agents; Calibration; COVID-19 Drug Treatment; Humans; Least-Squares Analysis; Pyrazines	2022
Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir. Journal of fluorescence, 2022, Volume: 32, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; COVID-19 Drug Treatment; Humans; Pandemics; Pyrazines; SARS-CoV-2	2022
Potential and action mechanism of favipiravir as an antiviral against Junin virus. PLoS pathogens, 2022, Volume: 18, Issue:7 Topics: Amides; Antiviral Agents; Arenavirus; Hemorrhagic Fever, American; Humans; Junin virus; Pyrazines; RNA-Dependent RNA Polymerase; Virus Replication	2022
Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study. PloS one, 2022, Volume: 17, Issue:7 Topics: Amides; Arthritis; COVID-19 Drug Treatment; Dietary Supplements; Humans; Longitudinal Studies; Pandemics; Pyrazines; Quality of Life; SARS-CoV-2; Vaccination; Vitamin D; Vitamins	2022
Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Nov-15, Volume: 281 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pyrazines; SARS-CoV-2; Spectrometry, Fluorescence	2022
Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis. Antiviral research, 2022, Volume: 205 Topics: Amides; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutagenesis, Site-Directed; Pyrazines; RNA-Dependent RNA Polymerase; Virus Replication; Viruses	2022
Sensitive and selective bioscreening of the most commonly used coronavirus disease drug, Favipiravir, and its co-administered therapeutic, Meropenem, in human plasma. Journal of separation science, 2022, Volume: 45, Issue:20 Topics: Chromatography, High Pressure Liquid; Coronavirus; Humans; Meropenem; Pyrazines; Reproducibility of Results	2022
IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 Intervention. ACS nano, 2022, 09-27, Volume: 16, Issue:9 Topics: Amides; Artificial Intelligence; Auranofin; COVID-19 Drug Treatment; Guanosine Monophosphate; Humans; Phosphoramides; Pyrazines; SARS-CoV-2	2022
Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTV. Viruses, 2022, 07-28, Volume: 14, Issue:8 Topics: Amides; Animals; Disease Models, Animal; Humans; Mice; Mice, Knockout; Phlebovirus; Pyrazines; Receptor, Interferon alpha-beta; Ribavirin; Solvents; Thrombocytopenia	2022
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nature communications, 2022, 08-30, Volume: 13, Issue:1 Topics: Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Humans; Macaca fascicularis; Pandemics; Primates; Pyrazines; SARS-CoV-2; Zika Virus; Zika Virus Infection	2022
Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Adult; Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome	2023
Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR. Molecules (Basel, Switzerland), 2022, Aug-31, Volume: 27, Issue:17 Topics: Alkalies; Amides; Chromatography, High Pressure Liquid; Pyrazines; Suspensions; Tandem Mass Spectrometry	2022
Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach. Drug design, development and therapy, 2022, Volume: 16 Topics: Amides; Antiviral Agents; Carvedilol; Cefixime; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drugs, Investigational; Humans; Ligands; Molecular Dynamics Simulation; Pyrazines; SARS-CoV-2; Viral Proteins	2022
Electrochemical Sensing of Favipiravir with an Innovative Water-Dispersible Molecularly Imprinted Polymer Based on the Bimetallic Metal-Organic Framework: Comparison of Morphological Effects. Biosensors, 2022, Sep-19, Volume: 12, Issue:9 Topics: Amides; Antiviral Agents; Electrochemical Techniques; Electrodes; Metals; Molecular Imprinting; Molecularly Imprinted Polymers; Polymers; Pyrazines; Water	2022
Efficient rescue of a newly classified Ebinur lake orthobunyavirus with GFP reporter and its application in rapid antiviral screening. Antiviral research, 2022, Volume: 207 Topics: Amides; Animals; Antiviral Agents; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Orthobunyavirus; Pyrazines; Ribavirin; Tyrphostins; Virus Replication	2022
Case report: Novel treatment regimen for Frontiers in immunology, 2022, Volume: 13 Topics: Amides; Antiviral Agents; Encephalitis, Viral; Enterovirus; Enterovirus Infections; Fluoxetine; Humans; Immunoglobulins, Intravenous; Infant; Male; Pyrazines	2022
Investigation of developmental toxicity of favipiravir on fetal bone and embryonic development. Birth defects research, 2022, 10-15, Volume: 114, Issue:17 Topics: Amides; Animals; Antiviral Agents; COVID-19; Embryonic Development; Female; Fetus; Pregnancy; Pyrazines; Rats; Rats, Wistar	2022
Effect of low and high dose of favipiravir on ovarian and reproductive function in female rats: Biochemical and histopathological evaluation. General physiology and biophysics, 2022, Volume: 41, Issue:5 Topics: Amides; Animals; Antioxidants; Antipsychotic Agents; Antiviral Agents; Female; Ovary; Oxidants; Pyrazines; Rats; RNA-Dependent RNA Polymerase	2022
Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity. International journal of molecular sciences, 2022, Sep-20, Volume: 23, Issue:19 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cryoelectron Microscopy; Humans; Molecular Docking Simulation; Nucleosides; Polyphosphates; Pyrazines; Reproduction; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2	2022
Severe mammarenaviral disease in guinea pigs effectively treated by an orally bioavailable fusion inhibitor, alone or in combination with favipiravir. Antiviral research, 2022, Volume: 208 Topics: Amides; Animals; Anti-Retroviral Agents; Arenaviridae; Guinea Pigs; Hemorrhagic Fever, American; Hemorrhagic Fevers, Viral; Junin virus; Mice; Pyrazines	2022
Fabric phase sorptive extraction combined with high performance liquid chromatography for the determination of favipiravir in human plasma and breast milk. Journal of pharmaceutical and biomedical analysis, 2023, Jan-20, Volume: 223 Topics: Chromatography, High Pressure Liquid; Female; Humans; Limit of Detection; Milk, Human; Pyrazines	2023
PIONEER trial: favipiravir to treat moderate COVID-19. The Lancet. Respiratory medicine, 2023, Volume: 11, Issue:5 Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Treatment Outcome	2023
HPLC-DAD quantification of favipiravir in whole blood after extraction from volumetric absorptive microsampling devices. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023, Jan-15, Volume: 1215 Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; COVID-19; Humans; Pyrazines	2023
Identification of novel inhibitors against hantaviruses through 2D fingerprinting and molecular modeling approaches. Frontiers in immunology, 2023, Volume: 14 Topics: Molecular Docking Simulation; Molecular Dynamics Simulation; Orthohantavirus; Pyrazines	2023
Tautomerism and Rotamerism of Favipiravir and Halogenated Analogues in Solution and in the Solid State. The Journal of organic chemistry, 2023, 08-04, Volume: 88, Issue:15 Topics: Amides; COVID-19; Humans; Pyrazines; Solvents	2023
In vitro and in vivo testing of the antiviral effect of favipiravir (T705) against the neurotropic Chandipura virus. Journal of medical virology, 2023, Volume: 95, Issue:7 Topics: Amides; Antiviral Agents; Humans; Pyrazines; Vesiculovirus	2023
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA. Acta clinica Croatica, 2022, Volume: 61, Issue:3 Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pneumonia; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome	2022